



EVER 2004

P R O G R A M M E

Vilamoura, Portugal • September 24 - 27

www.ever.be



Visionary

Introducing Pfizer Ophthalmics

We're committed to a future where no one goes blind because of ocular diseases and disorders. To get there, we're helping people in Asia and Africa fight a leading cause of blindness—trachoma. And, of course, our researchers are hard at work developing a new generation of breakthrough medicines in key areas of unmet need, including glaucoma, macular degeneration, and diabetic retinopathy.

Pfizer Ophthalmics. Dedicated to finding breakthrough medicines and to supporting the patients who benefit from them and the healthcare professionals who prescribe them.





a word from the president

Dear colleagues,

I want to wish you all very welcome to the 2004 meeting of EVER. This year, EVER takes another step on the European map and for the first time holds the annual meeting in the beautiful environment of Vilamoura, Portugal.

EVER constitutes the European effort for new developments in eye research and international exchange of basic science in ophthalmology. EVER aims to develop new ideas and promote rapid coupling between recent knowledge in physics, chemistry, engineering and information technology and clinical ophthalmology.

Please, dig into this year's program and you will find that in 2004, the members have managed to improve the quality even a little further compared to previous years. Special interest symposia, free papers and poster presentations make up the main structure of the meeting. Some of the posters get some additional publicity as a rapid fire presentation. These are excellent opportunities for authors and interested colleagues to connect for further discussion around the poster. The 2004 Ophthalmic Research lecture will reveal the mysteries of TGF β in the anterior segment. There are keynote lectures on dry eye, cataract epidemiology, diabetic retinopathy phenotypes, and astrocyte form and function. This year's AER-lecture will bring us up to date on the possibility of using gene information for design of therapy for retinal disease. Our past president will lead us on his track towards "Puzzles and Paradoxes".

Furthermore, there are instructional courses on "How to organize clinical studies", "Interactive course on visual fields in optic nerve and pathway diseases" and "Electrophysiology".

EVER provides a natural ground for scientific exchange and for establishment and consolidation of national and international collaboration. Official such examples are Euretina and the Ocular Oncology Task Force Group.

With several new countries in the European Union, I think one of the most important future opportunities for EVER is to try to attract as many as possible of all the skillful researchers in ophthalmology in the new member states.

It is a great pleasure for me to, on behalf of the EVER board, wish you all welcome to the EVER 2004 meeting. I look forward to seeing you in Vilamoura.



Per Söderberg

EVER President 2004

About EVER...

EVER, the European Association for Vision and Eye Research, is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange activities.

Membership

Membership is open to individuals of any nationality engaging in or having an interest in ophthalmic and vision research who meet the requirements established by the EVER Board. To become a member, a candidate shall apply to the General Secretary on the membership form. The application must be endorsed by one member and the applicant shall pay an application fee. If the candidate does not know any member who can endorse his/her application, he/she should attach a letter explaining the situation. The candidate becomes a member upon recommendation by the EVER Board and upon payment of the dues. The meetings of EVER are open to members and non members. However, only members and candidate members can submit material for a presentation.

Any group within EVER may organise symposia, workshops or other activities within a meeting. Any proposal should be sent to the Programme Secretary or to the scientific section representative before the end of the preceding year.

Elections

This year new representatives of the scientific sections **Anatomy / Cell biology** and **Vision Sciences / Electrophysiol. / Physiol. Optic.** will be elected through electronic voting. The result of the elections will be announced at the General Assembly on Monday.

The scientific sections will hold their Business Meetings on Saturday from 19:00 till 20:00. The sections on **Neuro-ophthalmology** and on **Oncology / Pathology** will nominate candidates for the succession of their representatives in the Board of EVER. The statutes and by-laws are available on the website: www.ever.be » [about](#) » [statutes](#)



Executive Committee

President	P Söderberg, Stockholm
Past president	A Bron, Oxford
Secretary General	J Jonas, Mannheim
Treasurer	A Wegener, Bonn
Programme Secretary	JJ De Laey, Gent
President Elect	N Galloway, Nottingham
Vice-president Elect	F van der Werf, Amsterdam

Chair of sections

Anatomy – Cell biology	F van der Werf, Amsterdam
Cornea – Ocular surface	H Dua, Nottingham
Glaucoma	S Orgul, Basel
Immunology – Microbiology	U Pleyer, Berlin
Lens and cataract	R Michael, Barcelona
Molecular biology – Genetics – Epidemiology	A Churchill, Bristol
	F Mascarelli, Paris
Neuro-ophthalmology – Strabismology	A Safran, Geneva
Pathology – Oncology	T Kivela, Helsinki
Physiology – Biochemistry – Pharmacology	I Haefliger, Basel
Retina – Vitreous	Ch Riva, Sion
Vision sciences – Electrophysiol. – Physiol. Optic.	N Galloway, Nottingham

Regional Representatives

G Maraini, Parma
P Aydin, Ankara
G Hollo, Budapest

Local Organisers

J Cunha-Vaz, Coimbra
R Proenca, Coimbra

EVER Office

Kapucijnenvoer 33
B-3000 Leuven, Belgium
Tel. +32 – 16.233.849
Fax +32 – 16.234.097

marlene.verlaeckt@ever.be
maarten.truyens@ever.be

www.ever.be

Location

EVER 2004 will be held in the **Marinotel** in Vilamoura, Algarva, Portugal from Friday 24 September till Monday 27 September 2004.

The **scientific programme** begins on Friday at 14:00 and concludes Monday at 19:00. The **EVER Welcome Party** starts on Friday at 19:30 and is open to all registered participants.

Registration

Everyone attending the scientific sessions—whether or not an EVER-member, invited speaker, accompanying person or presenter—must register and pay the registration fee.

The pre-registration deadline is September 1, 2004. At any time, you can register and pay your registration fee on-line at www.ever.be using your credit-card. If you do not register on-line, you can still register on-site in Vilamoura starting from Friday at 12:00.

Please note that

- being or becoming an EVER-member or having an abstract accepted does not imply that you are registered: all first authors must register
- if you register as a member in training, you need to proof your traineeship by showing a document signed by the Head of your Department
- if you register for OOTF-only, you cannot attend other scientific sessions
- if you register as an accompanying person, you are not allowed to attend the scientific sessions
- Refunds—up to 75% of the registration fee—will be granted for cancellation, received in writing, prior to September 15, 2004. Refunds will not be granted for later cancellation or no-shows.

Registration fees (in EUR) after September 1, 2004

EVER-member of SIS-invited speaker	250
Member in training	140
Non-member	400
Non-member in training	210
Course	70
OOTF-only (no access to other sessions)	80
Accompanying person	80

Website

The EVER website www.ever.be has a central role in the EVER organisation. At this website, you can

- obtain up-to-date information about the scientific programme and the EVER 2004 meeting
- pay on-line and obtain an overview of past payments
- view the status (session, hour, place) of your presentation
- look for other EVER-members
- get general information about EVER
- express your vote



Travel

Vilamoura can be reached in less than 20 minutes from Faro Airport. Because the Algarve is a popular tourist destination, there are many flights to Faro airport, either direct or via Lisbon.

Transportation

A **shuttle bus** will operate between Faro airport and Vilamoura on Friday (8:00 – 21:00), Monday (19:00 – 21:00) and Tuesday (6:00 – 12:00). Taxis are also available at the airport.

Weather

Vilamoura has an exceptional climate and offers sun all year round. Average temperature in September is around 25° Celsius, with about 10 hours of daily sun.

Touristic information

Vilamoura is the name of an area rather than a town. It covers about 2000 hectares of land, partly with vegetation, partly with forests. Thanks to the size of the resort area, it offers nearly every visitor nearly every form of sport and entertainment: four different golf courses, a large marina, a lawn bowling club, a tennis centre, sports club, shooting club, tourist apartments, night clubs, international casino, cinema and riding school. In the center of Vilamoura, there is a preserved Roman site and Museum of Cerro da Vila. In the neighbourhood of Vilamoura, there is the small fishing village called Quarteira and the commercial and administrative town of Loulé.



Information about the meeting of 2004

Social programme

The social programme is open for all participants and registered accompanying persons.

On **Friday**, there is the EVER Welcome Party, in the Marinotel. On **Sunday**, the EVER congress dinner takes place in the garden of the Marinotel.

Coffee

Coffee and soft drinks are provided, free of charge, during the meeting from 09:30 till 12:30 and from 15:00 till 17:30.

Internet access


Internet access is available in the PC-Room when no PC-course takes place. Furthermore, wireless internet access ("WiFi") will be available in the PC-Room and at the Registration desk.

Scientific programme access

You can visit www.ever.be for the most up-to-date scientific programme. A CD-ROM—sponsored by Alcon—is included with this programme book. All abstracts will be published in Volume 36, Supplement 1, 2004 of Ophthalmic Research. This abstract book will be available on-site in Vilamoura.

Poster prizes, sponsored by the AER

A poster prize of 400 EUR will be awarded every day. It will be decided on the ballot at the end of each day and will be given to the poster with the most votes. The 3 winners will be announced on Monday at the end of the poster session.



PC Data projection

A single beamer for pc-projection is provided in each hall. This is a modern beamer that can handle all conventional resolutions, although a standard resolution of 1024x768 pixels is recommended. The beamer cannot be used at the same time as the video projection.

EVER provides a modern pc (Office XP / Windows XP, English version) in each hall, so you do not have to bring your own laptop. Bringing your laptop with you is discouraged, not only because of theft risks (especially at airports) but also because of the hassle of branching this machine between presentations. We prefer your presentation on a CD, DVD or memory key. ZIP-drives are not allowed.

Please try to stick to standard Microsoft Powerpoint presentations. Other presentation programs (Apple Keynote, Corel Presentations, Staroffice / OpenOffice) can be used of course, but there is always a small risk involved.

You can check the projection in the preview room, a few hours before your presentation. Hand in your CD / DVD / memory stick to our technical staff. They will assist you to solve any compatibility problem you might encounter.

If you really insist on using your own laptop for whatever reason, please make solid arrangements with our technical staff. 30 minutes before the start of the session you must bring your laptop to the lecture hall. You should start your computer programme before the session begins, to prevent delay between presentation. Time lost while fumbling with the computer will not be compensated.

Upon request and after arrangements with our technical staff, Apple Macintosh computers can be used. Do not forget to bring your own connector cables: modern Apple Powerbooks often use "DVI" (digital) output ports, which need a small cable to convert DVI to standard VGA (analog). Apple iBooks often need a special cable as well to be branched to a beamer.

Video projection

A videoplayer with support for both VHS and SVHS (but no long-play VHS) is provided. It reads PAL (European) video cassettes.

Please note that the video projection cannot be used simultaneously with pc (Powerpoint) projections.

Check your video in the slide reception room before your presentation. Video's which have not been announced and checked at the slide reception room cannot be shown. Please contact our technical staff to make sure everything will work as expected.

**Slide projection is no longer supported.
Please use Powerpoint instead.**

Posters

Each poster is exhibited for one day only. You should install your poster in the morning between 08:00 and 09:00 and remove it the same day after 19:00. EVER is not responsible for any poster left behind at the end of the day.

You will find the number of your posterboard in one of the poster sections of this programme book (at the end of each day). The size of the posterboards is 190 cm wide x 100 cm high (landscape orientation).

You should be attending the poster session between 16:30 and 17:30. Please vote for the poster prizes by placing your ballot in the ballot boxes in the poster area.

Withdrawals

First authors unable to attend EVER for reasons beyond their control, may request permission of the Programme Secretary to have another author present the paper. Alternatively, they should send a written notice of withdrawal to the EVER Office before September 15, 2004.

Please note that any first author whose paper is not presented once it has been accepted, will be prohibited from presenting papers at EVER for the next two years.





ever 2004

Friday 24 September



Gemini I

How to organize clinical studies

14:00 – 17:00

Andrew SMITH

Course**I**

The aim of this course is to provide an introduction to the essential tools and techniques used in the design and analysis of data for clinical trials and outcomes research in ophthalmology.

The course assumes no previous knowledge of statistics or epidemiology and examples will be provided to show how clinicians can develop testable hypotheses to provide greater clinical evidence. Participants will also be encouraged to bring their own problems or study ideas with them to work on.

The goal is to increase the capacity of clinicians to do high quality epidemiologic and outcomes research in the realm of ophthalmology.

Gemini III

Interactive course on visual fields in optic nerve and pathway diseases

14:00 – 17:00

Pinar AYDIN

Course**II**

This course will cover general information on “Visual fields pathway and patterns in visual field testing”, “Artefacts in visual field tests”, “Various visual field testing techniques” during the first 40 minutes.

During the second 40 minutes examples of various cases with optic nerve and optic pathway will be interactively discussed. Participants are welcome to bring challenging clinical cases and contribute to the discussion.

This course will be in co-operation with **Seyda UGURLU, MD (Izmir, Turkey)** and **Tomasz ZARNOWSKI, MD (Lublin, Poland)**.

Vega

Electrophysiology

14:00 – 17:00

Graham HOLDER

Course**III**

The electrophysiology course is aimed at clinicians and scientists interested in the investigation of retinal and visual pathway function. This would include those practicing ophthalmic electrophysiology who desire an update, medical retina specialists, neuroophthalmologists, and those involved with paediatric ophthalmology.

Introduction to electrophysiological techniques (15 mins)

Graham HOLDER, Moorfields Eye Hospital, London, UK

The investigation of unexplained visual loss (40 mins)

Werner SPILEERS, University Hospital, Leuven, Belgium

Electrophysiology in combination with imaging techniques in retinal disorders (40 mins)

Marko HAWLINA, University Hospital, Ljubljana, Slovenia

Beyond the ISCEV standard. (40 mins)

The use of advanced techniques such as S-cone ERGs, ON/OFF- responses, extended dark adaptation etc.

Graham HOLDER, Moorfields Eye Hospital, London, UK

Please remember that you need to register separately if you want to participate in a course.

General Assembly

17:00 – 17:15, Fenix III

EVER Opening Ceremony

Introduction by Per SÖDERBERG

Ophthalmic Research Lect.

17:15 – 18:00, Fenix III

TGFβ in the anterior eye segment: its significance for immuneprivilege and glaucoma

Elke Lütjen DRECOLL—Erlangen

Introduction by Charles RIVA

Keynote Lecture

18:00 – 18:45, Fenix III

EVER Lecture: Of Puzzles and Paradoxes

Anthony BRON—Oxford

Introduction by Per SÖDERBERG

General Assembly

18:45 – 19:30, Fenix III

EVER Extraordinary General Assembly**Agenda**

- President's address
- Report of the Programme Secretary
- Miscellanea

Social Activity

19:30 – 22:00, Marinotel garden

EVER Welcome Garden Party



ever 2004

Saturday 25 September



Gemini I	Free Paper session: Uveitis	08:30 – 10:00
FP	Andrew David DICK, Francine BEHAR-COHEN	

08:30	1111	HLA-B35 antigen is associated with susceptibility to ocular opportunistic infections in patients with aids VERONESE RODRIGUES ML, GARDIM DEMARCO AL, FIGUEIREDO JFC, SOUZA NV, PAULA JS, ROMÃO E, DONADI EA–Ribeirão Preto, São José do Rio Preto
08:42	1112	Antigen presentation in a retina YAMAKI K, HARA K, KAMAYA S–Akita
08:54	1113	15 PGJ2 inhibit interferon gamma induction of MHC class II on RPE cells through a PPAR gamma and a CIITA independent mechanism WILLERMAIN F, CABAY L, DULKU S, BLERO D, DRIESSENS G, DE GRAEF C, MIOT F, SUAREZ N, VELU T, CASPERS L, BRUYNS C–Brussels
09:06	1114	CCL-5 (RANTES) Chemokine promoter gene Polymorphism and need for immunosuppressant agents in posterior uveitis MISSOTTEN T, AHAD M, ABDALLAH A, LYMPANY P, MENEZO V, KUO NW, LIGHTMAN S–London
09:18	1115	CCR-5 Chemokine receptor gene Polymorphism and severe outcome in posterior uveitis MISSOTTEN T, AHAD M, ABDALLAH A, MENEZO V, KUO NW, LYMPANY P, LIGHTMAN S–London

Gemini III	Free Paper Session: Physiology - Pharmacology	08:30 – 10:00
FP	Ivan O HAEFLIGER, Leopold SCHMETTERER	

08:30	1121	Modulation of retinal vascular diameter and choroidal blood flow in vasospastics ZAWINKA C, ORGUL S, REINHARD G, BRANKA F, FLAMMER J–Basel
08:42	1122	Role of NO in the control of choroidal blood flow during a decrease in ocular perfusion pressure POLSKA E, LUNG S, SIMADER C, WEIGERT G, KOLODJASCHNA J, SCHMETTERER L–Vienna
08:54	1123	Effects of Timolol and Dorzolamide on Ocular Blood Flow in Patients with Open Angle Glaucoma and Ocular Hypertension FUCHSJÄGER-MAYRL G, RAINER G, WALLY B, AMOAKO MENSAH T, GEORGOPOULOS M, VASS C, SCHMETTERER L–Vienna
09:06	1124	Does retinal venous vessel response depend on temporal frequency of chromatic flicker application? LANZL I, MUECKE B, VILSER W, KOTLIAR K–Munich, Ilmenau
09:18	1125	Short time increase of intraocular pressure does not alter the response of retinal veins to diffuse luminance flicker GARHOFER G, RESCH H, WEIGERT G, SIMADER C, SCHMETTERER L–Vienna
09:30	1126 <i>rf</i>	Local retinal venous reaction to moderate artificial IOP increase in normals and glaucoma patients KOTLIAR K, NAGEL E, VILSER W, LANZL I–Munich, Rudolstadt, Ilmenau
09:36	1127 <i>rf</i>	The assessment of conjunctival hyperemia with latanoprost 0.005% versus travoprost 0.004% therapy SIEGEL LI, SAROLI TL, JENKINS JN, STEWART WC, PRZYDRYGA JT–Southfield, MI, Charleston, SC, Fort Worth, TX
09:42	1128 <i>rf</i>	Volume of hypotensive eyedrops: Potential influence factors ANTON LOPEZ AAL, MARTIN MARTIN BMM, BLAZQUEZ ARAUZO FBA–Valladolid
09:48	1129 <i>rf</i>	Dynamic autoregulation in the eye and brain KOLODJASCHNA J, BERISHA F, POLSKA E, SCHMETTERER L–Vienna

Pegasus	Free Paper Session: Genetics	08:30 – 10:00
FP	Amanda CHURCHILL, Jochen GRAW	

08:30	1131	A study of the genetic background of corneal subepithelial haze following refractive surgery SZABO V, BALOGH K, HUNYADY L, NAGY ZZ–Budapest
08:42	1132	Identification of XLR51 gene mutation (608C>T) in a portuguese family with juvenil retinoschisis TEIXEIRA C, ROCHA-SOUSA A, BRANDÃO E, FALCÃO-REIS F–Porto
08:54	1133	Lebers Hereditary Optic Neuropathy in Turners syndrome COLLINS C E, BACKHOUSE O–Leeds
09:06	1134	Prevalence of PITx2 mutation/polymorphism in patients with primary open angle glaucoma VAIDEANU D, IDREES F, SOWDEN J, FRASER S–Sunderland, London
09:18	1135	The role of apolipoprotein E gene promoter polymorphisms in primary open angle glaucoma RESSINIOTIS T, VOROS GM, GRIFFITHS PG, KEERS S, BIRCH MK, CHINNERY PF–Newcastle upon Tyne
09:30	1136	Three novel Pax6 mutations in mice lead to small eyes and cataract, but have different functional consequences on target promoters GRAW J, LÖSTER J, MEYER B, NÜRNBERG P, SOEWARTO D, FUCHS H, SELBY P, FAVOR J, PRETSCH W, WOLF E, HRABÉ DE ANGELIS M–Neuherberg, Berlin-Buch, Oak Risse, München

Vega **Free Paper Session: Anatomy - Cell Biology** 08:30 – 10:00
 FP Erich KNOP, Frans VAN DER WERF

08:30	1141	Laminins in human extraocular muscles: clues to protection in muscle dystrophy PEDROSA-DOMELLÖF F, KJELLGREN D, VIRTANEN I—Umeå, Helsinki
08:42	1142	Uncoordinated expression of myosin heavy chains and myosin binding protein C isoforms in human extraocular muscles KJELLGREN D, STAL P, LARSSON L, FURST D, PEDROSA-DOMELLÖF F—Umeå, Uppsala, Potsdam
08:54	1143	NPY(+) AND TH(+) Intrinsic choroidal neurons in humans ROJAS B, DE HOZ R, SALAZAR JJ, RAMIREZ JM, TRIVIÑO A—Madrid
09:06	1144	A Method for Obtaining Progenitor Cells from Adult Rodent and Human Eyes VOSSMERBAEUMER U—Heidelberg
09:18	1145	Proteasome inhibitor -induced cytoplasmic protein aggregation is modified with geldanamycin in human ARPE-19 cells KAARNIRANTA K, RYHÄNEN T, MIETTINEN R, SALMINEN A, UUSITALO H—Kuopio, Finland
09:30	1146	Neural stem cells transplantation is protective to rabbit's retina function against kainate-induced excitotoxicity ZUEVA MV, TSAPENKO IV, CHENTSOVA EV, PAK NV, PETRIASHVILI GG, POLTAVTSEVA RA, MAREY MV, SUKHIKH GT—Moscow

Fenix I **Free Paper Session: Retina 1 - Physiology / Physiopathology** 08:30 – 10:00
 FP Gabriel COSCAS, Paula SUMMANEN

08:30	1151	Connective tissue growth factor is associated with fibrosis in vitreoretinal disorders in the human eye SCHLINGEMANN RO, KUIPER EJ, DE SMET MD, VAN MEURS JC, TAN HS, TANCK MW, OLIVER N, WIETEN L, VAN NIEUWENHOVEN FA, GOLDSCHMEDING R—Amsterdam, Rotterdam, San Francisco, CA, Utrecht
08:42	1152	Is erythropoietin involved in diabetic retinopathy? Preliminary communication DE SOUZA RAMALHO P, PEREIRA DA SILVA A, THIRAN C, FONTES G, BICHO MM—Lisbon
08:54	1153	Sympathetic and parasympathetic cardiovascular neuropathy and diabetic retinopathy SUMMANEN PA, MÄKIMATTILA S, SCHLENZKA A, MÄNTYSAARI M, YKI-JARVINEN H—Helsinki
09:06	1154 <i>rf</i>	Qualitative and Quantitative Comparison Of Autofluorescence And Color Images of Eyes with Drusen And Age Related Macular Degeneration SIVAGNANAVEL V, SMITH RT, CHAN J, FITZKE F, WEBSTER AR, JENKINS SA, CHONG NV—London, New York
09:12	1155 <i>rf</i>	Effects of vitamin C on hyperoxia-induced reduction of retinal blood flow LUKSCH A, WEIGERT G, MAÁR N, RESCH H, SCHMETTERER L—Vienna
09:18	1156 <i>rf</i>	Preterm Birth and Retinovascular Development FIELDER AR, COCKER KD—London
09:24	1157 <i>rf</i>	Expression of apoptosis markers in retinas of human subjects with diabetes ABU EL ASRAR AM, DRALANDS L, MISSOTTEN L, AL-JADAAN IA, GEBOES K—Riyadh, Leuven

Fenix III **Free Paper Session: Cornea 1 Clinical** 08:30 – 10:00
 FP Per FAGERHOLM

08:30	1161	Recurrent corneal erosions-a second family with autosomal dominant inheritance FAGERHOLM PPP, HAMMAR B, LIND H, BJORCK E, LAGERSTEDT K, DELLBY A, NORDENSKJOLD M—Linköping, Hudiksvalls, Sweden, Stockholm
08:42	1162	Morphological changes in a corneal dystrophy where recurrent erosions dominate FAGERHOLM PPP, EK S, SEREGARD S, HAMMAR B, DELLBY A, STENEVI U—Linköping, Mölndal, Stockholm
08:54	1163	Usefulness of pachymetry in Weill-Marchesani syndrome GICQUEL JJG, QUINTON JQ, SALAMA BS, GILBERT BG, DIGHERIO PLD—Poitiers, Saint Jean d'Angély
09:06	1164	Subbasal nerves and possible dendritic cells in diabetic patients by in vivo scanning-slit confocal microscopy POPPER M, QUADRADO MJ, MORGADO AM, MURTA JN, VAN BEST JA, MÜLLER LJ—Coimbra, Amsterdam
09:18	1165	In vivo confocal microscopic imaging of corneal limbal epithelial and central Langerhans cells (LCs) NUBILE M, TOTO L, LANZINI M, MASTROPASQUA L—Chieti
09:30	1166 <i>rf</i>	Highly reflective cells in the stroma of diabetic patients visualized by in vivo confocal microscopy QUADRADO MJ, POPPER M, MORGADO AM, VAN BEST J, MURTA JN, MÜLLER LJ—Coimbra, Amsterdam
09:36	1167 <i>rf</i>	Corneal involvement in pseudoexfoliation syndrome SKINNER KC, SRINIVAS HV, GREGORY PTS—Hastings

Keynote Lecture

10:15 – 11:00, Fenix III

Mechanisms of corneal epithelial diseases in dry eye

Stephen C PFLUGFELDER—Houston, TX

Introduction by Antony BRON

Gemini I		<i>Vogt-Koyanagi-Harada disease: developments in immunopathology and clinical appraisal</i>	11:00 – 12:30
SIS		Ahmed ABU EL ASRAR, Carl P HERBERT	
11:00	1211	Clinical, Epidemiological and Immunopathogenic Aspects MOCHIZUKI M–Tokyo	
11:15	1212	Animal models of VKH YAMAKI K, TAKIYAMA T, ITHO N, HAYAKAWA K, KAMEYA S–Akita, Yokohama	
11:30	1213	Chemokines and matrix metalloproteinases in VKH ABU EL ASRAR AM, STRUYF S, DESCAMPS FJ, AL-OBEIDAN SA, PROOST P, VAN DAMME J, OPDENAKKER G, GEBOES K–Riyadh, Leuven, Belgium	
11:45	1214	Ocular and systemic clinical signs and diagnosis in VKH BODAGHI B–Paris, France	
12:00	1215	Importance of ancillary and new imaging methods in VKH disease HERBERT CP–Lausanne	
12:15	1216	Vogt-Koyanagi-Harada disease - Complications and Therapy ABU EL ASRAR A–Riyadh	

Gemini III		<i>Improving classification of malignant uveal melanoma</i>	11:00 – 12:30
SIS		Tero KIVELA, Edoardo MIDENA	
11:00	1221	An overview of the TNM system and its objectives KIVELA T, KUJALA E–Helsinki	
11:17	1222	How should ciliary body extension be classified DAMATO B, TAKTAK A–Liverpool	
11:34	1223	How should extraocular extension be classified ZOGRAFOS L, FOR THE OPHTHALMIC ONCOLOGY TASK FORCE–Lausanne	
11:51	1224	What are additional clinical tumor characteristics that should be considered for the classification DESJARDINS L, PLANCHER C, LUMBROSO L, LEVY C, DENDALE R, ASSELAIN B–Paris	
12:08	1225	What are the histopathological tumor characteristics that could be considered for classification SEREGARD S–Stockholm	

Pegasus		<i>Free Paper Session: Lens UVR</i>	11:00 – 12:30
FP		Ralph MICHAEL	
11:00	1231	Ocular (side-) effects of pharmaceutical compounds and their specific interaction with cataract development WEGENER A–Bonn	
11:30	1232	Maximum tolerable dose for ultraviolet radiation induced cataract on repeated exposures with 30 days time interval DONG X, SÖDERBERG PG, LÖFGREN S, AYALA M, MODY V, KAKAR M, MEYER L–Stockholm	
11:42	1233	Metabolic changes in the anterior segment of the eye induced by UV irradiation and measured by NMR spectroscopy MIDELFART A, RISA Ø, SÆTHER O, TESSEM MB, FRIS M, SØDERBERG PG, CEJKOVA J–Trondheim, Stockholm, Prague	
11:54	1234	Oxidative stress and intercellular communication PEREIRA P, FERNANDES A, FERNANDES R, CATARINO S, GIRAO H–Coimbra	
12:06	1235	P53 expression in the lens after ultraviolet radiation (UVR) exposure <i>rf</i> AYALA MN, STRID H, DONG X, SÖDERBERG PG–Örebro, Stockholm	

Vega	Epidemiology and genetics of refractive error		11:00 – 12:30
SIS	Seang Mei SAW, Eric YAP, Donald T TAN		
11:00	1241	Molecular mechanisms of emmetropization and experimental myopia BEUERMAN R, BARATHI A, WEON SR–Singapore	
11:15	1242	Genetics of human refractive errors YAP E–Singapore	
11:30	1243	Myopia: prevalence rates and risk factors SAW SM–Singapore	
11:45	1244	Myopia and associated ocular morbidity WONG TY–Singapore	
12:00	1245	Clinical trials of lens treatment of myopia control GWIAZDA J–Boston, MA	
12:15	1246	Clinical trials of atropine and pirenzepine to retard myopia TAN D, CHUA W H–Singapore	
Fenix I	Free Paper Session: Retina 2 - Pharmacology		11:00 – 12:30
FP	Ingrid KREISSIG, Murat KARACORLU		
11:00	1251	Intravitreal Triamcinolone Acetonide for Retinal Diseases: Increased Risk of Repeat Injections? KREISSIG I, JONAS J, DEGENRING R, KAMPPETER B–Mannheim	
11:12	1252	Morphologic Changes in Diabetic Macular Edema After Intravitreal Triamcinolone Acetonide KARACORLU M, OZDEMIR H, KARACORLU S, ALACALI N–Istanbul	
11:24	1253	Evaluation of Macular Changes, Using Ocular Coherence Tomography (OCT) After Photodynamic Therapy and Intravitreal Triamcinolone in CNVM TEUS MA, ALVAREZ MT, ARRANZ-MARQUEZ E, MARTIN B–Madrid	
11:36	1254	Posterior juxtasclear delivery of anecortave acetate for treatment of exudative AMD COSCAS G, SOUBRANE G, SOUIED E–Créteil	
11:48	1255	Photodynamic therapy combined with intravitreal triamcinolone to treat CNV: preliminary results RUIZ MORENO JM, BARILE S, MONTERO J–Alicante	
12:00	1256	Reinjection Rates of Intravitreal Triamcinolone <i>rf</i> YILMAZ G, GEDIK S, AKKOYUN I, AKOVA Y–Ankara	
Fenix III	Free Paper Session: Cornea 2 Clinical		11:00 – 12:30
FP	Harminder S DUA, Niels EHLERS		
11:00	1261	Corneal regeneration with the use of autologous plasma rich growth factors (PRGF) ABAD M, SCORSETTI D, RODRIGUEZ-PRATS JL, ALIÓ JL–Alicante	
11:12	1262	Impression Cytology in the Follow-up of Ocular Burns treated with Amniotic Membrane Transplantation BALAYRE SB, GICQUEL JG, DIGHERO PLD–Poitiers	
11:24	1263	Amniotic Membrane transplantation for severe bacterial keratitis BALAYRE SB, GICQUEL JG, MERCIÉ MM, DIGHERO PLD–Poitiers	
11:36	1264	Triggering of endothelial cell mitosis by electric pulses THURET G, MANISSOLLE C, CAMPOS-GUYOTAT L, GARRAUD O, GAIN P–Saint-Etienne	
11:48	1265	Bioadhesives to seal corneal lacerations <i>rf</i> ABAD M, MULET ME, SANCHEZ A, SCORSETTI D, ALIÓ JL–Alicante	
11:54	1266	Corneal epithelial cell homeostasis in organ culture <i>rf</i> SOLTANINIA J, ARMITAGE WJ, BOULTON M, ALBON J–Cardiff, Bristol	
12:00	1267	Induced expression of insulin like growth factor 1 by amniotic membrane conditioned medium in cultured human corneal epithelial cell <i>rf</i> LEE HK, MA KT, SEONG GJ, LEE JH, SEO KR, KIM EK, CHUNG SH–Seoul	
12:06	1268	Is the corneal endothelial change that seen after 2.45 GHz microwave exposure (near ICNIRP safety limits) microwave exposure specific? <i>rf</i> KOJIMA M, HATA I, WAKE K, WATANABE S, TAKI M, KAMIMURA Y, YAMANAKA Y, TAKAHASHI N, SASAKI K–Daigaku, Uchinada, Kahoku-gun, Ishikawa, Nukui-Kitamachi, Koganei, Tokyo, Minami-Osawa, Hachioji, Tokyo, Utsunomiya	

Gemini I **New therapeutic modalities in uveitis** 14:00 – 15:30
SIS Marc D DE SMET, Uwe PLEYER

14:00	1311	Remicade European Study for Chronic Uveitis (RESCU) DE SMET M
14:15	1312	Fluocinolone Acetonide Intravitreal Implant in the Treatment of Posterior Segment Uveitis: One Year Results DE SMET M, FLUOCINOLINE ACETONIDE UVEITIS STUDY GROUP—Amsterdam
14:30	1313	Anti-TNF. The British experience DICK AD—Bristol
14:45	1314	Selective steroid receptor agonists (SEGRA) a future therapeutic option? PLEYER U—Berlin
15:00	1315	Deep sclerectomy to manage refractory glaucoma in uveitis HERBORT CP, AUER C, MERMOUD A—Lausanne

Gemini III **FRO 1** 14:00 – 15:30
Joint M. Marie - José TASSIGNON

14:00	1321	The role of cell adhesion molecule expression by the conjunctiva in the outcome of filtering surgery in glaucoma KLEIN A—Brussels
14:18	1322	Can topical NSAID or corticosteroid treatment pre-trabeculectomy alter drug-induced conjunctival fibrosis? STALMANS I—Leuven
14:36	1323	Physiopathology of the lens capsule after implantation of an intraocular lens (IOL) DE KEYZER K—Antwerp
14:54	1324	Follow-up of aberration changes after IOL insertion: comparison of various lens types ROZEMA J—Antwerp
15:12	1325	Genotype-Phenotype Correlations in Patients with Leber Congenital Amaurosis and their Carrier Parents DE BAERE E—Gent

Pegasus **Free Paper Session: Lens Biochemistry** 14:00 – 15:30
FP Teodosio LIBONDI

14:00	1331	The influence of Src-family tyrosine kinases on lens Na,K-ATPase DELAMERE NA, DEAN WL, TAMIYA S, BOZULIC LD—Louisville, KY
14:12	1332	Inhibition of glycogen synthase kinase (GSK-3) in the lens KARLSSON JO, PETERSEN ANNE—Gothenburg
14:24	1333	Proteasome-dependent degradation of Cx43 in lens epithelial cells requires the carboxyl-terminal of the protein CATARINO S, GIRAO H, PEREIRA P—Coimbra
14:36	1334	Distribution of the type of cataract and cell density in type II diabetics and nondiabetics - a scheimpflugdensitometric and histomorphological study STRUCK HG, TKACHOV SI, LAUTENSCHLÄGER C, EHRICH D—Halle
14:48	1335	Determination and quantification of kynurenic acid, a tryptophan derivative in cataractous lenses ZARNOWSKI T, ZIELINSKA-RZECKA E, REJDAK R, KOCKI T, ZAGORSKI ZF, TURSKI WA—Lublin
15:00	1336	Biochemical changes in selenite cataract model: Measurements by HR-MAS 1H NMR spectroscopy FRIS M, TESSEM MB, SÆTHER Ø, MIDELFART A—Trondheim
15:12	1337	Anticataractogenic Properties of Methylglyoxal-modified Small Heat Shock Proteins NAGARAJ RH, OYA-ITO T, LIU BF, BHAT M, PILCH HA—Cleveland

PC-Room **Using Microsoft Word I** 14:00 – 15:30
PC-Course Maarten TRUYENS



Using styles • Using headers, footers, footnotes and endnotes • Do's and don'ts for making a great-looking document • Making and sending PDF-files instead of Word-files via e-mail

Keynote Lecture

15:45 – 16:30, Fenix III

Cataract at the Cross Roads: Increasing blindness, challenges for research

Sheila WEST—Baltimore, introduction by Philippe KESTELYN

Vega **Gordon RUSKELL memorial symposium** 14:00 – 15:30
 SIS Frans VAN DER WERF

- 14:00 1341 Gordon Ruskell's Contributions to Ophthalmic Anatomy
BRON AJ–Oxford
- 14:10 1342 Innervation of the Anterior Eye Segment: a Tribute to Gordon Ruskell
VRENSEN GFJM–Leiden
- 14:20 1343 Sensory receptors in extraocular muscles
BRUENECH JR, KJELLEVOLD HAUGEN IB–Kongsberg
- 14:30 1344 The structure, distribution and putative function of corpuscular nerve endings in the human conjunctiva
LAWRENSON JG–London
- 14:40 1345 The puzzle of the rami orbitales and the relation to the retro-ocular plexus
VAN DER WERF F–Rotterdam

Fenix I **Free Paper Session: Retina 3 - Subretinal newvessels - Laser treatment** 14:00 – 15:30
 FP Anita LEYS, Gisèle SOUBRANE

- 14:00 1351 Transscleral diode laser delivery (Diopexyâ) for treatment of Subretinal choroidal neovascular membranes
RUIZ-LAPUENTE C J, PLAZAS A, VÁZQUEZ C, MUÑOZ A–Sevilla
- 14:12 1352 Axial Myopia Significantly Reduces Laser Dose in Verteporfin Therapy
NASCIMENTO JCN, DIAS JMD, CASTANHEIRA DINIS ACD–Lisboa
- 14:24 1353 Pseudophakic Implantation in High Myopic Eyes Induces Laser Dose Reduction in Verteporfin Photodynamic Therapy
DIAS JMD, NASCIMENTO JCN, CASTANHEIRA DINIS ACD–Lisboa
- 14:36 1354 Krypton laser treatment of chorioretinal anastomoses associated with vascularised retinal pigment epithelial detachment in AMD at the earliest stage: Ten consecutive cases
COSCAS G, DARMON J, COSCAS F, ZOURDANI A, SOUBRANE G–Creteil, Nice, Paris
- 14:48 1355 Missed re-treatments in photodynamic therapy
SERES A–Budapest
- 15:00 1356 Photodynamic Therapy for Subfoveal Choroidal Neovascularization Secondary to Vogt-Koyanagi-Harada Syndrome
rf NOWILATY SR, BOUHAIMED M, ABBOD EB, KAHTANI E, DHIBI H, AL-HARTHI E, JOHNSTON M, AL ROBAIE M, BANTAN I–Riyadh
- 15:06 1357 Diode laser (diopexyâ) transmission trough sclera
rf PLAZAS A, RUIZ-LAPUENTE C–Sevilla

Fenix III **Keratoprothesis 1** 14:00 – 15:30
 SIS Christopher LIU

- 14:00 1361 The international keratoprotheses scene
LIU C–Brighton
- 14:10 1362 Strampelli Osteo-Odonto-Keratoprothesis. Experience from 1964 to 2004
BARRAQUER J–Barcelona
- 14:20 1363 Update of OOKP results in Brighton
PAUL B, TANDON R, HEROLD J, THORP S, LIU C–Brighton
- 14:30 1364 Oculoplastic complications of OOKP surgery
MAVRIKAKIS I, BRITAIN P, HEROLD J, COLLIN JRO, LIU C–Brighton
- 14:40 1365 Surgery of the vitreous and retina in cases operated for osteo-odonto keratoprothesis
BARRAQUER J, NADAL J–Barcelona
- 14:50 1366 Developing a visual function questionnaire for OOKP patients
TANDON R, LEE E, PAUL B, HEROLD J, LIU CSC–New Delhi, Brighton
- 15:00 1367 The psychology of blindness and sight restoration
LEE E, TANDON R, PAUL B, THORP S, HEROLD J, LIU C–Brighton
- 15:10 1368 BioKPro II results at Moorfields Eye Hospital
WATSON S, HOLLIICK EJ, DART JKG, ALLAN BD–London

Poster session

16:30 – 17:30, Neptuno

Retina 1, cornea 1, anatomy / cell biology, uveitis, lens

Frederick William FITZKE, Gursel YILMAZ, Carl P HERBORT, Frans VAN DER WERF

Gemini I **Scleritis** 17:30 – 19:00
SIS Yan GUEX-CROSIER

17:30	1411	Anatomical and histological aspects of the sclera; Classification of scleritis MOSCHOS MM–Athens
17:45	1412	Orbit and inflammatory diseases HAMEDANI M–Lausanne
18:00	1413	Rheumatismal diseases and scleritis VAUDAUX J–Los Angeles
18:15	1414	Anterior segment ICG and imaging GUEX-CROSIER Y–Lausanne
18:30	1415	Scleritis in Ocular Sarcoidosis MORA P–Parma
18:45	1416	Immunosuppressive therapy DOAN S–Paris

Gemini III **FRO 2** 17:30 – 19:00
Joint M. Marie - José TASSIGNON

17:30	1421	Effect of nucleotides on retinal pigment epithelium proliferation in vitro BOUFFIOUX C–Brussels
17:48	1422	To evaluate the potential for incorporation of hippocampal stem cells in damaged retina BLAISE P–Liège
18:06	1423	Optimisation of adeno-associated virus gene transfer in the whole retina DE GREEF S–Brussels
18:24	1424	Inhibition of Intra-ocular inflammation mediated by adeno-associated virus gene transfer of SOCS1 and IκBm KOCH PH–Brussels
18:42	1425	Optimisation of the therapeutic activity of PLGA nanoparticles loaded with antibiotics (ciprofloxacin) for the treatment of infections of the outer eye DILLEN K–Antwerp

Pegasus **Free Paper Session: Lens Clinical** 17:30 – 19:00
FP Alfred WEGENER, Per SODERBERG

17:30	1431	Changes of the human lens capsule thickness between 30 and 100 years of age MICHAEL R, ABREU R, TRESSERRA F, BARRAQUER R I–Barcelona
17:42	1432	Investigation of the long-term safety of the *Acri.Tec AR-1 PC/IOL in rabbit eyes: an intraocular lens with reversibly adjustable optical power KAMPETER BA, FROMBERG I, FESSER N, ALLGOEWER I, JAHN CH, WAKILI NS, HOFMANN-RUMMELT CR, HOLBACH LM, JAHN CE–Mannheim, Hengnigsdorf, Erlangen, Kempten
17:54	1433	Implantation of an intraocular lens with reversibly adjustable optical power: *Acri.Tec AR-1 PC/IOL JAHN CE–Kempten
18:06	1434	The role of case mix in the relationship between volume and outcome in phacoemulsification surgery. HABIB MS, BUNCE CV, FRASER SG–Sunderland, London
18:18	1435	Outcome of Phacoemulsification in Patients with Uveitis ELGOHARY MA, MCCLUSKEY P, TOWLER H, SINGH R, OBIKPO R, OKHRAVI N, DOWLER JF, LIGHTMAN S–London, Sydney
18:30	1436	Intraocular Lens movement under ciliary contraction can be enhanced GALAND A, HUA MT–Liège

19:00 – 20:00 Business Meetings of the scientific sections:

Agenda

1. Report of the scientific officer	Anatomy / cell biology, immunology / microbiology, cornea / ocular surface, lens and cataract, glaucoma, molecular biology / genetics / epidemiology, neuro-ophthalmology
2. Report of the Programme Secretary	/ strabismology, retina / vitreous, pathology / oncology, vision sciences / electrophysiol. /
3. Next year's meeting:	physiol. optics and physiology / biochemistry / pharmacology.
nomination of a section programme secretary	
proposals of Special Interest Symposia	In addition to the agenda at the left, the sections neuro-ophthalmology and oncology / pathology will nominate candidates for scientific officer.
4. Comment on the EVER activities	
5. Other business	

Vega		Free Paper Session: Cornea Molecular Biology	17:30 – 19:00
FP		Berit BYSTRÖM, Paul Louis DIGHIRO	
17:30	1441	Expression of J-chain in the Normal Human Conjunctiva and Ocular Adnexa KNOP E–Berlin	
17:42	1442	Ultrastructural features and quantitative analysis of proteoglycans and collagen fibres of in keratoconus corneal stroma AKHTAR S, BRON AJ, SALVI SM, TUFT S, HAWKSWORTH NR, MEEK KM–Cardiff, Oxford, Llantrisant, London	
17:54	1443	Effect of native wild type and mutant recombinant keratoepithelin on corneal cells GLAVINI A, KHAN I, ALBON J, CAI J, BLACK GCM, BOULTON ME–Cardiff, Manchester	
18:06	1444	Laminins in normal, keratoconus, bullous keratopathy and scarred human corneas BYSTRÖM B, PEDROSA-DOMELLÖF F–Umeå	
18:18	1445	Corneal Connexin expression in Connexin 43 Knockout Mice GICQUEL JG, MILINCHEVITCH SM, SALAMA BS, BALAYRE SB, MESNIL MM, DIGHIRO PLD–Poitiers, Saint Jean d'Angély	
18:30	1446 <i>rf</i>	Cytokine Regulation of Extracellular Superoxide Dismutase Expression in Keratocytes from Human Corneas with Keratoconus or Bullous Keratopathy ÅSTRÖM EM, MARKLUND SL, BEHNDIG A–Umeå	
18:36	1447 <i>rf</i>	Surfactant Protein-D detected in corneal and conjunctival epithelium SUNDARAM V, BRON AJ, MCDONALD B, CLARK H, KNOP E–Oxford, Berlin	


Fenix I		Free Paper Session: Retina 4 - Surgery	17:30 – 19:00
FP		Constantin POURNARAS	
17:30	1451	Pneumatic Retinopexy in Patients with Pseudophakic Retinal Detachment YILMAZ G, GEDIK S, AYNACI B, AKKOYUN I, AKOVA Y–Ankara	
17:42	1452	Pars plana vitrectomy, retinotomy, subretinal injection of tissue plasminogen activator and gas, for the drainage of submacular hemorrhage in age-related macular degeneration BETIS F, DARMON J, LEGUAY JM, GASTAUD P–Nice	
17:54	1453	Enzymatic lysis and pneumatic displacement of subfoveal hemorrhage: Intravitreal rTPA and SF6 HENRICH PB, KONO-KONO JO, KLOPFER M, PFEILER T, KLAEBEN D–Munich, Eichstätt	
18:06	1454	ET-1 immunoreactivity of human idiopathic and proliferative vitreoretinopathy epiretinal membranes ROLDAN-PALLARES M, ROLLIN R, MEDIERO A, MARTINEZ-MONTERO JC, FERNANDEZ-CRUZ A, BRAVO-LLATA C, FERNANDEZ-DURANGO R–Madrid	
18:18	1455	Safety testing of intracyanine green using retinal pigment epithelium and glial cell cultures EL-AMIR AN, JACKSON TL, VOTE B, KNIGHT B, STANFORD M, MARSHALL J–London	

Fenix III		Keratoprosthesis 2	17:30 – 19:00
SIS		Christopher LIU	
17:30	1461	Keratoprosthesis at Bascom Palmer Eye Institute clinical experience and research advances FERNANDEZ V, STOIBER J, LAMAR PD, KAMINSKI S, LACOMBE E, DUCHESNE B, ACOSTA C, OROZCO M, HERNANDEZ E, ALFONSO E, PAREL JM–Miami, FL, Vienna, Paris, Liege	
17:40	1462	Glaucoma Following Keratoprosthesis Surgery DOHLMAN C–Boston, MA	
17:50	1463	Sudden, Presumed Sterile, Vitritis in Patients with Keratoprosthesis NOURI M, DURAND ML, DOHLMAN CH–Boston, MA	
18:00	1464	An update on the Coralline / Hydroxyapatite KPro LEON CR, BARRAQUER JI–Guatemala City, Bogota	
18:10	1465	AlphaCor artificial cornea data: An update HICKS CR–Nedlands	
18:20	1466	Keratocyte integration in biomimetic materials MEHTA JS, FUTTER C, ALLAN B–London	
18:30	1467	The effect of atmospheric plasma surface treatment of poly(methyl methacrylate) PMMA on corneal epithelial cell growth and protein absorption MOORE JE, SMALL D, FRAZER DG, MEENAN BJ, LIU C, ATKINSON SD, GRAHAM JE, DOWNES CS, MOORE CBT–Coleraine, Belfast, Jordanstown	
18:40	1468	Update on tissue engineered bio-synthetic corneas GRIFFITH M, LIU Y, CARLSSON DJ, LOHMANN CP, GAN L, LI F–Ottawa, Regensburg, Linköping	
18:50	1469	Novel composite materials for the fabrication of artificial corneae LLOYD AW, FRANKLIN V, ROSE S, MORRIS C, TIGHE BJ, LIU C–Brighton, Birmingham	

- 101 Trypan blue staining of epi-retinal membranes in proliferative vitreoretinopathy
ESPINOZA-NAVARRO J, MILDRED FROMOW-GUERRA M, MILDRED FROMOW-GUERRA M, MILDRED FROMOW-GUERRA, ARTHUR LEVINE-BEREBICHEZ, RENATA GARCIA-FRANCO-Mexico
- 102 Effects of vitamin C on hyperoxia-induced reduction of retinal blood flow
rf LUKSCH A, WEIGERT G, MAÄR N, RESCH H, SCHMETTERER L—Vienna
- 103 Preterm Birth and Retinovascular Development
rf FIELDER AR, COCKER KD—London
- 104 Diode laser (diopexyâ) transmission trough sclera
rf PLAZAS A, RUIZ-LAPUENTE C—Sevilla
- 105 Expression of apoptosis markers in retinas of human subjects with diabetes
rf ABU EL ASRAR AM, DRALANDS L, MISSOTTEN L, AL-JADAAN IA, GEBOES K—Riyadh, Leuven
- 106 Investigation of the effects of phototoxicity on photoreceptor function and visual outcome following arteriovenous sheathotomy surgery
MUQIT MMK, PARKS S, KEATING D, MURDOCH JR—Glasgow
- 107 Commotio retinae determined by optical coherence tomography
PIERRE-KAHN VPK, MICHOU D, CEDDAH AC, BOURGES JLB, RENARD GR, CHAUVAUD DC—Paris
- 108 Function of the visual system of patients treated with interferon alfa and ribavirin - The prospective study
POJDA-WILCZEK D, HERBA E, POJDA SM, PLECH AR, MAKOWIECKA-OBIDZINSKA K, ZATORSKA B, JEDRZEJEWSKI W, DZIAMBOR AP, STOLARZ W—Bytom
- 109 Pulsatile Ocular Blood Flow in Asymmetric Age Related Macular Degeneration.
SANDHU R, CHONG V—London
- 110 Age-specific visual loss in eyes with early Age-Related Maculopathy
SJÖSTRAND JB, BERGMAN B, POPOVIC Z—Molndal
- 111 Pulsatile Ocular Blood Flow Changes after Pan-retinal Photocoagulation and Macular Laser for Diabetic Retinopathy
SANDHU R, CHONG V—London
- 112 Cellular membrane content of occludin in an experimental model of diabetes
CARVALHO M, PROENÇA R—Coimbra
- 113 Combined phacovitrectomy and intraocular lens implantation: Pertinent steps in maintaining optimal per-operative visualisation of the anterior retina and posterior pole.
MUGHAL S, HERO M—Coventry
- 114 High Speed Indocyanine Green Angiography Guided Laser Treatment For Idiopathic Polypoidal Choroidal Vasculopathy; An Interventional Case Series.
LAUDE A, DJATIKUSUMO A, LEE JJ, NAH GKM, LIM TH—Singapore
- 115 Didanosine induced retinopathy in adults: an observational case series
ANDERSON OA, FERNANDO FI, PURI P, DAVIES NP, MITCHELL SM—London
- 116 Secretory phospholipase A2-IB in the human retina
KOLKO M, PRAUSE JU, HEEGAARD S, BAZAN NG—Copenhagen, New Orleans
- 117 Measuring macular pigment optical density with undilated pupil in one second
VAN NORREN D, VAN DE KRAATS J, BERENDSCHOT TTJM—Utrecht
- 118 Autofluorescence
GONZALVEZ BG, SARMENTO AS, MOUILLON MM—Grenoble
- 119 Macular pigment shows ring like structures
BERENDSCHOT TTJM, VAN NORREN D—Utrecht
- 120 Macular pigment optical density is independent of age
BERENDSCHOT TTJM, VAN NORREN D—Utrecht
- 121 Qualitative and Quantitative Comparison Of Autofluorescence And Color Images of Eyes with Drusen And Age Related Macular Degeneration
rf SIVAGNANAVEL V, SMITH RT, CHAN J, FITZKE F, WEBSTER AR, JENKINS SA, CHONG NV—London, New York
- 122 Mechanisms controlling permeability and junctional architecture of primary retinal endothelial cells in vitro
OCKRIM ZK, HYKIN P, TUROWSKI P, GREENWOOD J—London
- 123 Absorption of diode 810 nm TTT laser by blood in vitro
MUNOZ MORALES AM—Seville
- 124 Heme oxygenase-1 response to diabetes, hyperglycemia and oxidative stress in retinas and endothelial cells
AVELEIRA CA, LEAL EC, CASTILHO A, SERRA A, AMBRÓSIO AF—Coimbra
- 125 Visual prognosis in pseudovittelliform degeneration: A longitudinal study
FERNANDO A, PURI P, TALBOT JF—London, Sheffield
- 126 Photodynamic Therapy for Subfoveal Choroidal Neovascularization Secondary to Vogt-Koyanagi-Harada Syndrome
rf NOWILATY SR, BOUHAIMED M, ABBOD EB, KAHTANI E, DHIBI H, AL-HARTHI E, JOHNSTON M, AL ROBAIE M, BANTAN I—Riyadh
- 127 Effects of Photodynamic Therapy in the use of microscopes in patients with choroidal neovascularization secondary to pathological myopia and classic age-related macular degeneration
SOBRADO-CALVO P, GÓMEZ-RAMÍREZ AM, VARGAS-MARTÍN F, VILLEGAS-PÉREZ MP, MIRALLES DE IMPERIAL J—Murcia
- 128 Photodynamic Therapy using Verteporfin for juxtafoveal choroidal neovascularisation in Angioid Streaks associated with Pseudoxanthoma elasticum
CHUNG AKK, GAUBA V, GHANCHI FD—Leeds, Bradford
- 129 Peripapillary neovascularisation during Tamoxifen treatment
HERA R, TONINI M, MOUILLON M, ROMANET JP—Grenoble
- 130 Evolution of retinal thickness in a two year follow up of nonproliferative retinopathy in type 2 Diabetes
DUARTE L, FIGUEIRA J, BERNARDES RC, NUNES S, LOBO C, CUNHA-VAZ JG—Coimbra
- 131 High TGF-β2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy
DIEUDONNE SC, LA HEIJ EC, DIEDEREN R, KESSELS A, LIEM A, KIJLSTRA A, HENDRIKSE F—Maastricht
- 132 Preventive effect of subretinal injections of hRPE on synaptic relay in RCS rats
PINILLA I, SAUVÉ Y, CUENCA N, WANG S, LU B, LUND RD—Salt Lake City
- 133 Userfriendly software for the automated mosaic reconstruction of fundus digital retinography
GAVET Y, PEYROCHE C, DEB-JOARDAR N, THURET G, DINET E, GAIN P—Saint-Etienne
- 134 Erythropoietin plasma expression in diabetic retinopathy preliminary report
DE SOUZA RAMALHO P, PEREIRA DA SILVA A, THIRAN C, FONTES G, BICHO MM—Lisbon
- 135 Helicobacter pylori and retinal vein occlusion
VOIGT M, LE TIEN V, GLACET-BERNARD A, ZOURDANI A, COSCAS G, SOUBRANE G—Paris
- 136 Multiple retinal hemangioma-like lesions in retinitis pigmentosa
PENAS S, CARNEIRO A, VALVERDE J, MARTINHO R, FALCÃO-REIS F—Porto
- 137 Level of antibodies against retinal antigens in AMD patients
MISIUK HOJLO MH, JUROWSKA-LIPUT J, AGOPSOWICZ KA, BIALEK-SZYMANSKA ABS, GORCZYCA WG, KUROPATWA MK, WITKOWSKA DW—Wroclaw
- 138 Verteporfin therapy for subfoveal choroidal neovascularization in pathologic myopia
GOMEZ-RAMIREZ AM, MARTÍNEZ-MORALES JA, SOBRADO-CALVO P, VILLEGAS-PÉREZ MP, MIRALLES DE IMPERIAL J—Murcia
- 139 The management of retinal detachment in adult aphakes who have had congenital cataract surgery
MUGHAL S, HEGDE V, AL-HUSAINI S, HERO M—Coventry
- 140 Re-injection Rates of Intravitreal Triamcinolone
rf YILMAZ G, GEDIK S, AKKOYUN I, AKOVA Y—Ankara
- 141 Intravitreal triamcinolone acetate for treatment of intraocular proliferative, exudative and angiogenic diseases.
JONAS JB, KREISSIG I, DEGENERING RF—Heidelberg
- 142 Retinal circulation in diabetic retinopathy before and after panretinal photocoagulation
OKANO T, MATSUNO K—Ibaraki, Japan
- 143 Ultrastructural retinal changes in an experimental model of hypercholesterolemia. Variations after normalization of cholesterol blood values induced by a normal diet.
SALAZAR JJ, RAMÍREZ AI, DE HOZ R, ROJAS B, TRIVINO A, RAMIREZ JM—Madrid
- 144 Ultrastructural choroidal changes in an experimental model of hypercholesterolemia. Variations after normalization of cholesterol blood values induced by a normal diet.
RAMIREZ AI, SALAZAR JJ, ROJAS B, DE HOZ R, TRIVIÑO A, RAMIREZ JM—Madrid
- 145 Classification of Choroidal Neovascular Membrane Type in Age-Related Macular Degeneration using Optical Coherence Tomography - 3
KHAN AJ, HUGHES EH, PATEL N, KASHANI S, CHONG NV—London
- 146 Mitochondrial-DNA Control Region analysis in Diabetic Retinopathy
ABECIA E, PEIRO F, MARTÍNEZ-JARRETA B—Zaragoza
- 147 Retinitis pigmentosa with Coats-like exudative vasculopathy - a case report
FARKAS Á, VÁMOS R, BESCH D, SALACZ G—Budapest, Tübingen
- 148 Retinal and pupillary function recovery in severe ocular siderosis
PENAS S, ROCHA-SOUSA A, CAPÃO-FILIPE JA, FALCÃO-REIS F—Porto
- 149 Screening of diabetic retinopathy by digital retinograph: advantages of pharmacological dilatation
DEB N, THURET G, GAVET Y, MANOLI P, GARCIN A, GERMAIN N, MILLOT L, ESTOUR B, GAIN P—Saint-Etienne

Moderators: Frederick William FITZKE, Gursel YILMAZ, Carl P HERBORT, Frans VAN DER WERF

- 150 Intravitreal Triamcinolone Acetonide in eyes with macular edema associated with central retinal vein occlusion
GIRAUD JMG, RIGAL-SASTOURNÉ JCRS, OUBAAZ AO, RENARD JPR, MAURIN JFM—Paris
- 151 Vitreal glutamate concentration in rabbits after intravitreal injection of air, balanced saline solution, sulfur hexafluoride gas and perfluorocarbon liquid
VIEIRA DE SOUZA N, VIEIRA DE SOUZA E, AIHARA T, COUTINHO NETO J—Ribeirão Preto
- 152 Human macular pigment distribution from hyperspectral imaging of the fundus
BAPTISTA AMG, NASCIMENTO SMC, FOSTER DH—Braga, Manchester
- 153 Auto-ophthalmoscopy: Looking at one's own retina
ARMOUR R H—Stevenage, Hertfordshire
- 154 Highly reflective cells in the stroma of diabetic patients visualized by in vivo confocal microscopy
QUADRADO MJ, POPPER M, MORGADO AM, VAN BEST J, MURTA JN, MÜLLER LJ—Coimbra, Amsterdam
- 155 Corneal involvement in pseudoexfoliation syndrome
rf
SKINNER KC, SRINIVAS HV, GREGORY PTS—Hastings
- 156 Bioadhesives to seal corneal lacerations
rf
ABAD M, MULET ME, SANCHEZ A, SCORSETTI D, ALIÓ JL—Alicante
- 157 Corneal epithelial cell homeostasis in organ culture
rf
SOLTANINIA J, ARMITAGE WJ, BOULTON M, ALBON J—Cardiff, Bristol
- 158 Induced expression of insulin like growth factor 1 by amniotic membrane conditioned medium in cultured human corneal epithelial cell
rf
LEE HK, MA KT, SEONG GJ, LEE JH, SEO KR, KIM EK, CHUNG SH—Seoul
- 159 Is the corneal endothelial change that seen after 2.45 GHz microwave exposure (near ICNIRP safety limits) microwave exposure specific?
rf
KOJIMA M, HATA I, WAKE K, WATANABE S, TAKI M, KAMIMURA Y, YAMANAKA Y, TAKAHASHI N, SASAKI K—Daigaku, Uchinada, Kahoku-gun, Ishikawa, Nukui-Kitamachi, Koganei, Tokyo, Minami-Osawa, Hachioji, Tokyo, Utsunomiya
- 160 Cytokine Regulation of Extracellular Superoxide Dismutase Expression in Keratocytes from Human Corneas with Keratoconus or Bullous Keratopathy
rf
ÅSTRÖM EM, MARKLUND SL, BEHNDIG A—Umeå
- 161 Surfactant Protein-D detected in corneal and conjunctival epithelium
rf
SUNDARAM V, BRON AJ, MCDONALD B, CLARK H, KNOP E—Oxford, Berlin
- 162 Quantitative study of the tear film in a population of young adults
LIRA M, RESUA C, YEBRA-PIMENTEL VILAR E, REAL OLIVEIRA E—Braga, Santiago de Compostela
- 163 Qualitative study of the tear film in a population of young adults
LIRA M, RESÚA C, YEBRA-PIMENTEL VILAR E, REAL OLIVEIRA E—Braga, Santiago de Compostela
- 164 An artificial meniscus for study of tear properties
TIFFANY JM, WALLACE BJ—Oxford
- 165 The Application of Capillary Liquid Chromatography-Mass Spectrometry Techniques to the Study of Patient-to-patient Variations in Tear Chemistry
MANN AM, CAMPBELL D, TIGHE B—CEAC
- 166 Surface Wettability of Worn and Unworn Contact Lenses
TIGHE B, N ASSO M—CEAC SEAS, CEAC
- 167 Contact Lenses & Comfort Enhancers: In Vivo and In Vitro Release of Soluble PVA
MAHOMED A, TIGHE B—CEAC
- 168 The Application of Lab-on-a-Chip Technology in Tear Composition, Deposited Protein and Tear "Envelope" Analysis
MANN AM, TIGHE BJ—Birmingham
- 169 Comparative Physical and Biochemical Studies of Silicone Hydrogel Contact Lenses
FRANKLIN VJ, TIGHE BJ—CEAC
- 170 Results of a US Community-Based Evaluation of a Lubricating Eye Drop Containing HP-Guar
PRZYDRYGA J, HARTSTEIN I—Fort Worth, TX, La Palma, CA
- 171 Behaviour of human tenon fibroblasts after long term low dose beta irradiation
PICHLER A, GILBERT I, SCHUBERT M, ASSMANN W, KOTLIAR K, LANZL I—Munich, Garching
- 172 Distribution and organization of sympathetic human choroidal innervation
DE HOZ R, ROJAS B, RAMÍREZ AI, SALAZAR JJ, RAMÍREZ JM, TRIVIÑO A—Madrid
- 173 Unique M-band composition in human extraocular muscles
PEDROSA-DOMELLÓF F, CARLSSON E, CARLSSON L, THORNELL LE—Umeå
- 174 Bilateral Panuveitis Revealing Gluten Hypersensitivity
SALAMA BS, GICQUEL JGG, VABRES PV, DIGHIRO PLD—Saint Jean d'Angély, Poitiers
- 175 CMV retinitis in Good Syndrome
STANESCU D, BONNEL S, SALLÓ FB, SAHEL J—Paris, Budapest
- 176 An Unusual Case of Periorbital Necrotising Fasciitis With Implications for Future Management of the Condition
ROBBIE S J, MUHTASEB M, QURESHI K—London
- 177 Tacrolimus in the treatment of uveitis in children
VOROS GM, RESSINIOTIS T, PANDIT R—Newcastle Upon Tyne
- 178 Proliferation of peripheral blood lymphocytes in vitro and Interleukin-2 secretion in uveitic patients
URBAN E, MISIUK-HOJLO M, RUSIECKA J—Wrocław
- 179 CCL-5 and CCR-5 chemokine gene polymorphism in posterior non-infectious uveitis
AHAD M, MISSOTTEN T, ABDALLAH A, LYMPANY P, MENEZO V, KUO N-W, LIGHTMAN S—London
- 180 Should diagnosis of ocular toxocariasis be revisited?
LABALETTE PL, JAUMAIN-SPRIMONT A-S, DEWITTE J-M, DUTOIT E, CAMUS D, ROULAND J-F—Lille
- 181 Inflammatory cells and cytokines production in chalazia
FRUSCHELLI M, MASSAI L, CARBOTTI P, MENCARELLI M, ALESSANDRINI C, GRASSO G—Siena
- 182 Apoptotic Mechanisms in Staphylococcus epidermidis Experimental Endophthalmitis
PHARMAKAKIS N, VANTZOU C, PETROPOULOS I, ANASTASSIOU E, ZOLOTAS V—Patras
- 183 P53 expression in the lens after ultraviolet radiation (UVR) exposure
rf
AYALA MN, STRID H, DONG X, SÖDERBERG PG—Örebro, Stockholm
- 184 A Randomized prospective study comparing 3 methods for providing topical anaesthesia in cataract surgery
SHIEW M, NAGAR M, IONIDES A—London
- 185 Psychological and physiological effects of different type of local anaesthesia for cataract surgery
GOMBOSS K, JAKUBOVICS E, KUSNYERIK A, SALACZ GY—Budapest
- 186 Intra-operative complications of phacoemulsification
TAHHAN M, GOGI D, RACHDAN D, WEHBEH ML, THOMPSON S—West Bromwich, West Bromwich, Birmingham
- 187 Intraocular Eye Lash foreign Body
ISLAM N, DABBAGH A—London
- 188 The Relationship between the Effective Phaco Time (EPT) and Gender, Age at Surgery, Anterior Chamber Depth, Lens Thickness and Preoperative Visual Acuity
ELGOHARY MA, BECKINGSALE AA—Colchester
- 189 Visual Outcomes of cataract surgery and posterior chamber IOL implantation in AIDS patients
FERNANDO AI, PURI P, MITCHELL S—London, UK
- 190 AcrySof (SA60AT) and AcrySof Natural (SN60AT): can they be distinguished after intraocular implantation?
TEIXEIRA C, FREITAS S, ROCHA-SOUSA A, COENTRÃO L, CAPAO-FILPE J, FALCAO-REIS F—Porto
- 191 Nd:Yag capsulotomy and its effect on refractive status in patients with silicone foldable lenses
DE WIT DW, SALEH GM, GAUBA V, ALLEN R J—Colchester, Sidcup, South London, Leeds
- 192 A dynamic light scattering study of the reversibility of protein dynamics during cold cataract formation
PHARMAKAKIS N, PETTA V, PAPAETHODOROU G, YANNOPOULOS S—Patras
- 193 Pseudophakic monovision for good near and distance uncorrected visual acuity
JAHN CE, TÖPFNER VON SCHÜTZ K, JAHN SE, STROTMANN H—Kempten
- 194 Effect of ultraviolet radiation-B on development of cataract in albino rats in vivo and effect on lens ascorbate content
MODY VC JR, KAKAR MK, ELFVING Å, LÖFGREN S, AYALA M, DONG X, MEYER L, SÖDERBERG PG—Stockholm
- 195 Ascorbate effect on development of ultraviolet radiation-B (UVR-B)-induced cataract in cultured rat lenses
KAKAR MK, MODY JR VC, LUNDBERG B, ELFVING Å, LÖFGREN S, MEYER L, DONG X, AYALA M, SÖDERBERG PG—Stockholm
- 196 Genomic organization and mRNA heterogeneity of LENGGIN, a glutamine synthetase-like protein preferentially expressed in lens
GRASSI F, BETTI M, MARQUEZ A, MARAINI G, OTTONELLO S—Parma, Sevilla
- 197 The ubiquitin-proteasome pathway competes with heat shock proteins for denatured proteins in the lens
MARQUES C, PEREIRA P, GUO W, TAYLOR A, SHANG F—Coimbra, Boston
- 198 7-ketocholesterol stabilises ubiquitin activating enzyme E1 in lens epithelial cells
GIRAO H, CATARINO S, PEREIRA P—Coimbra
- 199 High glucose levels affects markers of oxidative stress and proteolytic activity in human lens epithelial cells and intact mouse lenses
PÅLSSON AZ, PETERSEN A, KARLSSON J-O—Göteborg



ever 2004

Sunday 26 September



Gemini I	Highlights of therapy for external eye disease	08:30 – 10:00
SIS	Anthony BRON, Clive WILSON	

BAUSCH & LOMB

08:30	2111	Novel modes of topical drug delivery WILSON C—Glasgow
08:45	2112	Steroid Action at the cellular level BRON AJ—Oxford
09:00	2113	Selecting and Monitoring Corticosteroid Use EASTY D—Bristol
09:15	2114	Mechanisms and Management of Ocular Allergy LEONARDI A, MOTTERLE L—Padova
09:30	2115	Newer Horizons in Ophthalmic Anti-infectives for Therapy of External Ocular Infections O'BRIEN T—Baltimore, Maryland
09:45	2116	Coping with Complex Ocular Surface Disease CURSIEFEN C—Boston, MA

Gemini III	Free Paper Session: Neuro-ophthalmology 1	08:30 – 10:00
FP	Pinar AYDIN, Ann HELLSTROM	

08:30	2121	Risk factors for visual loss in an italian population- based cohort of patients with giant cell arteritis CIMINO L, SALVARANI C, CAPPUCCINI L, BOIARDI L—Reggio Emilia, Italy
08:42	2122	Sudden loss of visual acuity in children and youth - diagnostic problems POJDA-WILCZEK D, HERBA E, POJDA SM—Bytom
08:54	2123	Inflammation of ciliar ganglion with retrobulbar optic neuritis symptoms - case report HERBA E, POJDA-WILCZEK D, POJDA SM, MAKOWIECKA-OBIDZINSKA K—Bytom
09:06	2124	Management of pseudotumor cerebri during pregnancy EL SHEHA H, EMARA E—Jeddah
09:18	2125	Airbag-induced eye injuries using eyewear MUNOZ MORALES AM, RUIZ LAPUENTE CR—Seville
09:30	2126	Glaucoma and optic nerve drusen <i>rf</i> KAWA P, NOWOMIEJSKA K, BIALEK M, HASZCZ D, CZOP DC, MANKOWSKA A, KRUKOWSKI J, ZAGÓRSKI Z—Lublin
09:36	2127	Doppler Velocities in Retrobulbar Arteries in Normal Pregnancy and Postpartum. A Longitudinal Study <i>rf</i> VIGANDER K, TAKSERMAN A, HAUGEN G, KERTY E—Oslo
09:42	2128	Influence of papilloedema on globe shape <i>rf</i> MADILL SA, CONNOR S—London

Pegasus	Morphology of the inner retina and optic nerve related to glaucoma	08:30 – 10:00
SIS	Christian Albrecht MAY	

08:30	2131	Comparative morphology of the inner retina and optic nerve head in animals used for glaucoma research MAY CA—Erlangen
08:50	2132	Does glial cell malfunction precede ganglion cell death in glaucoma? OSBORNE NN, CHIDLOW G, WOOD JPM—Oxford
09:10	2133	Expression of metabotropic glutamate receptors and associated proteins under elevated intraocular pressure in a mouse model for secondary angle-closure glaucoma ENZ R, MAY CA, DYKA FM—Erlangen-Nürnberg
09:30	2134	Morphological diversity in human glaucomatous optic nerves LÜTJEN DRECOLL E, MAY CA—Erlangen

AER Lecture

10:15 – 11:00, Fenix III

From gene to therapy: the long way to understand and cure retinal diseases

Eberhart ZRENNER—Tübingen

Introduction by Gijs VRENSSEN

Vega	OOTF 1		08:30 – 10:00
Joint M.	Laurence DESJARDINS, Edoardo MIDENA		
08:30	2141	Incidence of familial retinoblastoma: the experience of the Italian Referral Center HADJISTILIANOU T, DE FRANCESCO S, MARCONCINI S, MARTONE G, BATISTI C, MENICACCI F–Siena	
08:42	2142	Malignant lymphoma of the lacrimal sac. An EORTC study. SJÖ LD, AUW-HAEDRICH C, DELBOSC B, DUCREY N, JUHL BR, KANTELP B, KEMENY JL, KIVELÄ T, LUTHERT P, MEYER P, PRAUSE JU, RALFKIAER E, SJÖ NC, HEEGAARD S–Copenhagen, Freiburg, Besancon, Lausanne, Clermont-Ferrand, Helsinki, London, Basel	
08:54	2143	Lesions of the lacrimal drainage system. A clinicopathological study of 643 biopsy specimens of the lacrimal drainage system in Denmark 1910-1999. LINDEGAARD J, MARTIN JK, PRAUSE JU, HEEGAARD S–Copenhagen	
09:06	2144	Is Proton radiotherapy an alternative to radical surgery in the management of extended conjunctival melanoma? ANASTASSIOU G, MELLER D, SCHUELER AO, WUESTEMEYER H, SAUERWEIN W, CHAUVEL P, STEUHL P, BORNFELD N–Essen, Nice	
09:18	2145	Exfoliative cytology in conjunctival melanoma KEIJSER S, LUIJK VAN CM, MISSOTTEN GS, VESELIC-CHARVAT M, WOLFF-ROUENDAAL DE D, KEIZER DE RJW–Leiden	
09:30	2146 <i>rf</i>	Human papillomavirus - cause of epithelial lacrimal sac neoplasia? SJO NC, BUCHWALD C, FLAMANT P, HEEGAARD S, LINDEBERG H, NORRILD B, PRAUSE JU, ORTH G–Copenhagen, Paris, Aarhus	
09:36	2147 <i>rf</i>	Erdheim-Chester disease: severe orbital involvement treated by Vinblastin associated to Interferon TONINI M, SARROT-REYNAUD F F, BERNAL DESCOUR F, MOUILLON M, ROMANET JP–Grenoble	
09:42	2148 <i>rf</i>	Pilomatrixoma: A Reminder (Clinical & Histopathological Similarity to Basal Cell Carcinoma) TAHHAN M, BENSCHIN S, ASHWIN P, KASMIYA M–West Bromwich, Dudley	
09:48	2149 <i>rf</i>	Orbital involvement in multifocal fibrosclerosis HEEGAARD S, KYHN M, HERNING M, PRAUSE JU–Copenhagen, Hvidovre	
Fenix I	Workshop: Mouse Model & Phenotyping		08:30 – 10:00
SIS	Jochen GRAW		
08:30	2151	The Opto-kinetic test and funduscopy as a primary screen for vision in the mouse HART A, MCKIE L, MORGAN J, THAUNG C, CROSS SH, JACKSON IJ–Edinburgh	
08:48	2152	Intraocular pressure measurements in mice REITSAMER H	
09:06	2153	The ERG (Electroretinogram) is a suitable test for retinal function in mice DALKE C, GEKELER F, ZRENNER E, GRAW J–Neuherberg, Tübingen	
09:24	2154	Light scattering measurements in mouse lenses WEGENER A–Bonn	
09:42	2155	Screening Mice for Vision: Slit lamp and open questions GRAW J, LÖSTER J, FAVOR J–Neuherberg	
Fenix III	EURETINA: New therapeutic options in AMD		08:30 – 10:00
Joint M.	Gisbert RICHARD		
08:30	2161	Evidence for the Participation of Inflammation and Immune-mediated Pathways in the Etiology of Age-related Macular Degeneration HAGEMAN G–Iowa City	
08:42	2162	The Eyetech Anti-VEGF Study DEUTMAN A F, HOYNG C B, MEULENDIJKS C F M, SCHLINGEMANN R O–Nijmegen, Amsterdam	
08:54	2163	Lucentis in the Treatment of AMD LEYS A–Leuven	
09:06	2164	Anecortave Acetate in the Treatment of AMD DE SMET MD, VERBRAAK FD, MICHAUD JE–Amsterdam, Ft Worth	
09:18	2165	Photodynamic Therapy (PDT) in AMD. New Aspects SOUBRANE G–Créteil	
09:30	2166	Macular Translocation in AMD CORCOSTEGUI B–Barcelona	
09:42	2167	Acute Human Trial for Retina Implant Technology. Results of a Multicenter Study RICHARD G, FEUCHT M, LAUBE T, BORNFELD N, WALTER P, VELIKAY-PAREL M, HORNIG R–Hamburg, Essen, Aachen, Vienna, Bonn	

Gemini I	Dry Eye	11:00 – 12:30
SIS	Harminder S DUA, Jose GOMEZ	

11:00	2211	Classification and Nomenclature DUA HS–Nottingham
11:20	2212	Clinical Pathology of dry eye GOMES J–Sao Paolo
11:40	2213	Dry Eye tests: How useful are they? NIRANKARI VS–Owings Mills, Maryland
12:00	2214	Treatment Options in Dry Eyes PFLUGFELDER SC–Houston, TX

Gemini III	Free Paper Session: Neuro-ophthalmology 2	11:00 – 12:30
FP	John BARBUR	

11:00	2221	Tadpole pupil during bimedial recession correction of esotropia WEIR RE, ZAIDI FH, GREAVES BG, BREMNER F–London, Ashford Kent, Queens Square London
11:12	2222	Pupil constriction to red vs. achromatic light permits differentiation of macula-on from macula-off retinal detachments using pupillometry ZAIDI FH, WEIR RE, MOSELEY MJ–London
11:24	2223	Selective ETB1 stimulation relaxes the iris sphincter muscle ROCHA DE SOUSA A, SARAIVA J, FALCÃO-REIS F, LEITE-MOREIRA AF–Porto
11:36	2224	Achromatic Contrast Sensitivity in Parkinson's Disease FARIA P, SILVA M, CASTELO-BRANCO M, JANUARIO G, MASSANO J, REGATEIRO F, JANUARIO C, FREIRE A–Coimbra
11:48	2225 <i>rf</i>	Pupillometry reveals increased inter-eye pupil escape ratio in the eye with a subretinal membrane ZAIDI FH, MOSELEY MJ–London
11:54	2226 <i>rf</i>	Eye velocities during static fixation in patients with central scotoma MACEDO AF, GOMES AOS, NASCIMENTO SMC–Braga, Porto
12:00	2227 <i>rf</i>	Clinical pathways in glaucoma elaborated by a new pupillographic test (patent pending) KANDEL GL, KABACK M, SANCHEZ R–New York

Pegasus	Physiology and pharmacology of the optic nerve	11:00 – 12:30
SIS	Nicholas DELAMERE	

11:00	2231	Age-related Changes of the Rodent Optic Nerve MAY CA–Erlangen
11:20	2232	Visually-Evoked Hemodynamical Response and Neurovascular Coupling in the Human Optic Nerve RIVA CE, LOGEAN E, FALSINI B–Sion, Rome
11:40	2233	Protecting the optic nerve from injury OSBORNE NN, WOOD JPM, CHIDLOW G–Oxford
12:00	2234	Aquaporin water channels in optic nerve astrocytes: A role in homeostasis PATIL R–Nebraska, Omaha

PC-Room	Using Microsoft Powerpoint	11:00 – 12:30
PC-Course	Maarten TRUYENS	



Inserting images at the right resolution • Why don't my movies play? • Making sure your presentation plays correctly on another pc • Do's and don'ts for a great presentation

Vega	OOTF 2	11:00 – 12:30
Joint M.	Tero KIVELÄ	

11:00	2241	Malignant uveal versus conjunctival melanoma: which is worse? KUJALA E, TUOMAALA S, ESKELIN S, KIVELÄ T–Helsinki
11:12	2242	A review of metastatic uveal melanoma DESJARDINS L, LUMBROSO L, LEVY C, PIPERNO-NEUMAN S, DORVAL T, DENDALE R, SALMON R, MARIANI P, SASTRE X, ASSELAIN B, PLANCHER C–Paris
11:24	2243	Survival of patients with choroidal melanoma: correlation with histopathological features and monosomy 3 SANDINHA MT, FARQUHARSON M, MCKAY I, ROBERTS F–Glasgow
11:36	2244	Cytogenetics of uveal melanoma DAMATO B, CAMPBELL I, HOWARD P–Liverpool, Wirral
11:48	2245	S100B, S100 dimers and melanoma-inhibitory activity in uveal melanoma screening MISSOTTEN GS, KEUNEN JEE, BONFRER JGM, JAGER MJ–Leiden, Amsterdam
12:00	2246	Phase I/II study of frequent and prolonged immunization with NA17 and differentiation peptides in HLA-A2 patients with metastatic uveal melanoma : preliminary results PIPERNO-NEUMANN S, DORVAL T, LANTZ O, DESJARDINS L, SALMON R, POUILLART P, BRICHARD V–Paris, Rixensart
12:12	2247 <i>rf</i>	Effects of Glivec®/STI571 in human uveal melanoma cell MOURIAUX F, LEFEVRE G, CALIPEL A, GLOTIN AL, MASCARELLI F–Caen, Paris
12:18	2248 <i>rf</i>	A tale of two diagnoses : A case of ocular and intracranial tumors MISSOTTEN GS, LAAN LA, DE WOLFF-ROUENDAAL D, DE KEIZER RJW–Leiden

Fenix I	Oxidation and cataract	11:00 – 12:30
SIS	Anders BEHNDIG	

11:00	2251	Revival of inactivated enzymes from the human cataract lens HARDING JJ, RACHDAN D, LOU MF–Oxford, Lincoln
11:20	2252	The superoxide radical: relevance to photochemical and glucose induced cataractogenesis BEHNDIG A, ÅSTRÖM E–Umeå
11:40	2253	Role of ubiquitin in lens protein quality control: degradation versus repair SHANG F, GUO W, MARQUES C, TAYLOR A–Boston
12:00	2254	Oxidative damage and intercellular communication PEREIRA P, FERNANDES A, FERNANDES R, CATARINO S, GIRAO H–Coimbra

Fenix III	Retinal vein occlusions - Current concepts in pathogenesis and treatment	11:00 – 12:30
SIS	Murat KARACORLU, Constantin POURNARAS	



11:00	2261	Current Concepts in the Pathogenesis of Retinal Vein Occlusions. Goals of Treatment POURNARAS CJ–Geneva
11:12	2262	Hypercoagulable States and Retinal Vein Occlusions: Coagulation Status and the Necessary Laboratory Tests HATTENBACH LO, KUHLI C, OHRLOFF C–Frankfurt am Main
11:24	2263	Experimental retinal vein occlusion PAQUES M–Paris
11:36	2264	Acute phase medical treatment (hemodilution) HANSEN LL–Freiburg
11:48	2265	Assessment and follow-up of CME by OCT in retinal vein occlusions. The role of intravitreal steroids KARACORLU M–Istanbul
12:00	2266	Endovascular Surgery and tPA in Retinal Vein Occlusions FELTGEN NF, HERRMANN JH, HANSEN LH–Freiburg
12:12	2267	Current status of surgical decompression in retinal vein occlusions POURNARAS CJ, KARACORLU M–Geneva, Istanbul

Gemini I **Free Paper Session: Cornea 3 Tears - Dry Eye** 14:00 – 15:30
 FP Stephen C PFLUGFELDER, Prabhat MAUDGAL

14:00	2311	Effect of Human Tears on Cationic Antimicrobial Peptide Activity In Vitro MCDERMOTT AM, HUANG LC, NARAYANAN S–Houston
14:12	2312	Tear meniscus radius and tear film formation in healthy and dry eye states OWENS H, SUGITA J, YOKOI N, TIFFANY J, PHILLIPS JR, BRON AJ–Auckland, Nagoya, Kyoto, Oxford
14:24	2313	Tear-film dynamics after incomplete blinking ERDELYI B, NEMETH J–Budapest
14:36	2314	Vitamin A-responsive xerophthalmia MANGANELLI C, TURCO S, SCULLICA L–Roma
14:48	2315	Dry Eye and Corneal Sensitivity after High Myopic LASIK TUISKU ISJ, LINDBOHM N, TERVO TMT–Helsinki
15:00	2316 <i>rf</i>	Ocular & Dermal Hydration: The Role of Hydrogels in the Control of Moisturisation TIGHE B, BAHIA R–CEAC
15:06	2317 <i>rf</i>	Correlation of Schirmer test score and tear break up time with Ocular surface staining in Dry Eye disease SUNDARAM V, EVERY S, BRON AJ, SAMARASINGHE S, PRABHAKARAN E, VATHESATOGIT C–Oxford

Gemini III **Free Paper Session: Physiology - Pharmacology - Animal Studies** 14:00 – 15:30
 FP Neville OSBORNE, Clive WILSON

14:00	2321	Intravitreal levofloxacin monotherapy in endophthalmitis experimental model FERRER RODRIGUEZ C, FERNANDEZ CANILLAS J, RODRIGUEZ AE, ABAD LOZANO JL, ALIO JL–Alicante
14:12	2322	Evaluation of Retinal Leukocyte Adhesion in a Mouse Model of Diabetes WADDELL JM, MANIVANNAN A, COTTER MA, FORRESTER JV–Aberdeen
14:24	2323	Upregulation of ubiquitin proteasome pathway (UPP) in retinal endothelial cells in response to oxidative stress FERNANDES A, FERNANDES R, RAMALHO J, PEREIRA P–Coimbra
14:36	2324	Aldose reductase inhibition counteracts diabetes-induced retinal nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation OBROSOVA IG, SZABO C, STEVENS MJ, PACHER P–Baton Rouge, LA, Beverly, MA, Ann Arbor, MI, Rockville, MD
14:48	2325	Ghrelin relaxes the iris sphincter muscle through a GHSR-1A independent pathway ROCHA DE SOUSA A, SARAIVA J, GONZAGA S, CORREIA-PINTO J, FALCÃO-REIS F, LEITE-MOREIRA AF–Porto, Braga
15:00	2326 <i>rf</i>	Retinal endothelial cell dysfunction caused by hyperglycemia and oxidative stress CASTILHO A, SERRA A, LEAL EC, AVELEIRA C, AMBRÓSIO AF–Coimbra
15:06	2327 <i>rf</i>	Metipranolol is the only ophthalmic beta-blocker to counteract oxidative stress-induced death to cultured human RPE cells WOOD JPM, OSBORNE NN–Oxford
15:12	2328 <i>rf</i>	Expression of Monocarboxylate Transporters in the Rat Retina: Effects of Retinal Degenerations CHIDLOW G, WOOD JPM, GRAHAM M, OSBORNE NN–Oxford, Loughborough
15:18	2329 <i>rf</i>	Aqueous humour formation is inhibited by bradykinin via production of cyclic GMP WILSON WS, ALMALKI W, MARTIN W–Glasgow

Pegasus **Dendritic cells-key regulators of ocular antigen presentation** 14:00 – 15:30
 SIS Erich KNOP, Uwe PLEYER

14:00	2331	An introduction into Ocular Dendritic Cells KNOP E–Berlin
14:18	2332	Characteristics of DC in culture FORRESTER J–Aberdeen
14:36	2333	What have we learned from corneal transplantation about corneal APC? DANA R–Boston, MA
14:54	2334	Are there really no dendritic cells in the retina? DICK A–Bristol
15:12	2335	Unusual Phenotype of Dendritic Cells in the Mouse Conjunctiva ONO S, MANZOURI B, OHBAYASHI M–London

Keynote Lecture

15:45 – 16:30, Fenix III

Astrocyte form and function: implications for glaucoma

Nicholas DELAMERE—Louisville, Introduction by Neville OSBORNE

Poster session

16:30 – 17:30, Neptuno

Poster session: Pathology, oncology, neuro-ophthalmology, physiology, pharmacology, vision sciences

Frédéric MOURIAUX, Pinar AYDIN, Werner SPILEERS, Pierre LACHAPELLE

Vega	OOTF 3	14:00 – 15:30
Joint M.	Rita VAN GINDERDEUREN, Stefan SEREGARD	

14:00	2341	Ocular Hypertension Masquerading Uveal Melanoma BIANCIO T C, SAORNIL MA, BLANCO G, MUIÑOS Y, MENDEZ MC, FRUTOS BARAJA J, LOPEZ LARA F, ESTEBAN R, FERNANDEZ N–Valladolid
14:12	2342	Iodine Brachytherapy (IBT) for Large Ciliochoroidal Melanoma: Modeling Dose Distribution PUUSAARI I, HEIKKONEN J, KIVELA T–Helsinki
14:24	2343	Complications following plaque radiotherapy for uveal melanoma ROMANOWSKA DIXON B, MARKIEWICZ A, STARZYCKA M–Krakow
14:36	2344	Treatment of uveal melanoma near to the optic nerve or macula by strontium-90 brachytherapy VAN GINDERDEUREN R, SPILEERS W, VAN LIMBERGEN E–Leuven
14:40	2345	Intraocular seminoma metastases ROMANOWSKA DIXON B, ORLOWSKA-HEITZMAN J–Krakow
14:44	2346	Conjunctival nevus or malignant melanoma in a child BOGDANICI C, CARUNTU I, COZMA L–Iasi
14:48	2347	Conjunctival Rhabdomyosarcoma MENDEZ MC, BLANCO G, SAORNIL MA, SARASA JL, FERNANDEZ N–Valladolid, Madrid
14:52	2348	Wegener's granulomatosis confirmed after bilateral proptosis MENDEZ MC, BLANCO G, HERRERAS JM, MUIÑOS Y, PIGAZO JM–Valladolid
14:56	2349	Local chemotherapy with interferon-alfa as alternative treatment to radiotherapy in conjunctival malt lymphomas SAORNIL MA, BLANCO G, MENDEZ MC, MUINOS Y, SARASA JL, FERNANDEZ N–Valladolid, Fundacion Carolina, Madrid
15:00	234a	Cavitary uveal melanoma SAORNIL MA, BECERRA E, MENDEZ MC, BLANCO G, MUIÑOS Y, PIGAZO JM–Valladolid
15:04	234b	Enophthalmos as first manifestation of systemic spread of breast adenocarcinoma BIANCIO T C, BLANCO G, SAORNIL MA, MENDEZ MC, PIGAZO JM–Valladolid
15:08	234c	Pleomorphic adenoma arising in an accessory lacrimal gland of Wolfring ALYAHYA GA, SKJODT K, PRAUSE JU, SAUNTE JP, HEEGAARD S–Copenhagen
15:12	234d	Uveal melanoma as a third malignant tumour ALJAMAL RT, KUJALA E, KIVELA T–Helsinki

Fenix I	Lens development and genetics	14:00 – 15:30
SIS	Jochen GRAW	

14:00	2351	PAX6 and SOX2 in eye disease and development VAN HEYNINGEN V–Edinburgh
14:18	2352	Control of proliferation and differentiation in the developing retina WITTBRODT J–Heidelberg
14:36	2353	Natural antisense transcripts (NATs) associated to genes involved in eye development BANFI S, ALFANO G, VITIELLO C, CACCIOPPOLI C, CARAMICO T, AURICCHIO A–Naples
14:54	2354	Role of AP2 transcription factor in lens development WEST-MAYS J, ASHERRY-PADAN R, WILLIAMS T, GRUSS P, PONTORIERO GF–Ontario, Israel, Colorado
15:12	2355	Aspects of eye development regulation in the aphakia mouse MUENSTER D, HORSCH M, DROBYSHEV AL, BECKERS J, GRAW J–Neuherberg

Fenix III	The European Vision Institute. Phenotyping of AMD	14:00 – 15:30
SIS	Jose CUNHA-VAZ, European Vision Institute	



14:00	2361	Autofluorescence measurements in ARMD FITZKE FW–London
14:18	2362	Multimodal macula mapping in ARMD BERNARDES R, SILVA R–Coimbra
14:36	2363	Electrophysiology in AMD and its relation to retinal imaging techniques ZRENNER E, SCHOLL HPN–Tübingen, Bonn
14:54	2364	Challenges for clinical trials SAHEL J–Paris
15:12	2365	Summary CUNHA-VAZ J–Coimbra

Gemini I	New combinations in glaucoma therapy	17:30 – 19:00
SIS	Anders HEIJL	



17:30	2411	Current trends in glaucoma medical therapy HEIJL A–Malmö
17:48	2412	Adjunctive options to PGA therapy AREND O–Alsdorf, Germany
18:06	2413	Switch, add or both GANDOLFI S–Parma
18:24	2414	Overview of Travoprost/Timolol Fixed Combination Phase III Trial Results DENIS P–Lyon

Gemini III	Free Paper Session: Vision Sciences	17:30 – 19:00
FP	Werner SPILEERS	

17:30	2421	Interactions between visual attention and illusory motion perception KOZAK LR, FORMISANO E, GOEBEL R, CASTELO-BRANCO M–Coimbra, Maastricht
17:42	2422	Complex motion processing in schizophrenia CASANOVA C, DUMBRAVA D, BILOTTO L, LACHAPELLE P, STIP E, PTITO M–Montreal
17:54	2423	The photopic light adaptation effect results from a gradual release of inhibition exerted on the off retinal pathway LACHAPELLE P, GARON M-L, CASANOVA C, RUFIANGE M–Montréal
18:06	2424	Contributions from lateral interaction mechanisms to the human ERG MEIGEN T, PRUEFER R, REIME S–Wuerzburg
18:18	2425	Chromatic properties of natural scenes from hyperspectral imaging NASCIMENTO SMC, FOSTER DH, AMANO K–Braga, Manchester
18:30	2426	The influence of cognitive content in detecting spatial changes of the illuminant colour in real three-dimensional scenes DE ALMEIDA VMN, NASCIMENTO SMC, FIADEIRO PT–Covilhã, Braga
18:42	2427 <i>rf</i>	Adaptive Optics: a new in vivo in situ non-invasive method toward a high resolution image of retinal photoreceptors SALAMA BS, GLANC MG, GICQUEL JG, LE GARGASSON JFL–Saint Jean d'Angély, Meudon, Paris
18:48	2428 <i>rf</i>	A method of retaining LogMAR visual acuity data in a "loss-less" fashion ANDERSON OA, FERNANDO FI, DAVIES NP–London

Pegasus	Stem and progenitor cells of the eye: from cell biology to clinic	17:30 – 19:00
SIS	Yvan ARSENIJEVIC, Erich KNOP, Francis MUNIER	

17:30	2431	Ocular surface biology: lessons from the clinic PELLEGRINI G, DI IORIO V, DE LUCA M–Venice
17:45	2432	Epithelial stem cells on ocular surface MAJO F, ROCHAT A, HOANG-XUAN T, BARRANDON Y–Lausanne, Paris
18:00	2433	Clinical significance of limbal corneal stem cells DUA HS–Nottingham
18:15	2434	Neural stem cells in the vertebrate eyes: types and regulation AHMAD I–Omaha
18:30	2435	Generation of retinal neurons from mouse and human retinal stem cells ARSENIJEVIC Y, ANGENIEUX B, MICHAULT L, GEHRING W, SCHORDERET DF, MUNIER FL–Lausanne, Basel, Sion

Vega	OOTF 4	17:30 – 19:00
Joint M.	Edoardo MIDENA	

Business meeting

Fenix I	Potentials for nutritional and therapeutical prevention of cataract	17:30 – 19:00
SIS	Shambhu D. VARMA, Per SÖDERBERG	

17:30	2451	Effectiveness of antioxidants against human cataract CHYLACK LT–Boston, MA
17:45	2452	Strategies in Cataract Prevention: Efficacy of Nutritional and Endogenously Derived Antioxidants and Metabolites HEGDE KR, VARMA SD–Baltimore
18:00	2453	Prevention of ultraviolet radiation cataract SÖDERBERG PG, LÖFGREN S, AYALA M, DONG X, KAKAR M, MODY V, MEYER L–Stockholm, Örebro
18:15	2454	Vitamins E, C, REACT or Beverage and Food Antioxidants to Reduce Risk of Cataract? TREVITHICK JR, PRICKETT C, COLLINS M, BANTSEEV V, HIRST M–London, Waterloo
18:30	2455	Structural Analogs of the Sorbitol Dehydrogenase Inhibitor 4-[4-(N,N-Dimethylsulfamoyl)piperazino]-2-hydroxymethylpyrimidine Delay Diabetic Cataract Formation KADOR P, INOUE J, BLESSING K–Omaha, Nebraska, Kobe
18:45	2456	Modulation of the chaperone function of alpha-crystallin by dicarbonyl compounds NAGARAJ RH–Cleveland

Fenix III	Free Paper Session: Retina 5 - Instrumentation & Techniques	17:30 – 19:00
FP	Sarah BENSON	

17:30	2461	Pars plana vitrectomy with intravitreal triamcinolone for diabetic macular oedema OCKRIM ZK, HYKIN P, EZRA E, GREGOR Z–London
17:42	2462	Optical Coherence Tomography Analysis Of The Macula After Successful Surgery For Retinal Detachment. BENSON S E, SCHLOTTMAN P, CHARTERIS DG–London
17:54	2463	Improved Resolution Retinal Thickness Mapping Using the Stratus OCT BERNARDES R, VARANDAS J, LOBO C, CUNHA-VAZ J–Coimbra
18:06	2464	Abnormal leakage mapping using the retinal leakage analyzer VARANDAS J, BERNARDES R, CUNHA-VAZ J–Coimbra
18:18	2465	The Retina Thickness Analyzer as a tool to evaluate drug efficacy in nonproliferative retinopathy in type 2 diabetic subjects NUNES S, BERNARDES R, LOBO C, CUNHA-VAZ J–Coimbra
18:30	2466	Automatic establishment of macular coordinates BAPTISTA P, BERNARDES R, DIAS J, CUNHA-VAZ J–Coimbra
18:42	2467	Optical coherence tomography in patients with achromatopsia VARSANYI B, SOMFAI GM, FARKAS Á–Budapest

PC-Room	Computer Q&A	17:30 – 19:00
PC-Course	Maarten TRUYENS	



This session is primarily meant to answer questions from session visitors, but will also cover popular questions such as Virus and security threats • avoiding e-mail spam • using alternatives for Microsoft Internet Explorer and Outlook

201 Human papillomavirus - cause of epithelial lacrimal sac neoplasia?
SJO NC, BUCHWALD C, FLAMANT P, HEEGAARD S, LINDEBERG H, NORRILD B, PRAUSE JU, ORTH G—Copenhagen, Paris, Aarhus
rf

202 Erdheim-Chester disease: severe orbital involvement treated by Vinblastin associated to Interferon
TONINI M, SARROT-REYNAUD F F, BERNAL DESCOUR F, MOUILLON M, ROMANET JP—Grenoble
rf

203 Pilomatrixoma: A Reminder (Clinical & Histopathological Similarity to Basal Cell Carcinoma)
TAHHAN M, BENSKIN S, ASHWIN P, KASMIYA M—West Bromwich, Dudley
rf

204 Orbital involvement in multifocal fibrosclerosis
HEEGAARD S, KYHN M, HERNING M, PRAUSE JU—Copenhagen, Hvidovre
rf

205 Effects of Glivec®/STI571 in human uveal melanoma cell
MOURIAUX F, LEFEVRE G, CALIPEL A, GLOTIN AL, MASCARELLI F—Caen, France, Paris
rf

206 A tale of two diagnoses : A case of ocular and intracranial tumors
MISSOTTEN GS, LAAN LA, DE WOLFF-ROUENDAAL D, DE KEIZER RJW—Leiden
rf

207 Treatment of uveal melanoma near to the optic nerve or macula by strontium-90 brachytherapy
VAN GINDERDEUREN R, SPILEERS W, VAN LIMBERGEN E—Leuven
rf

208 Co-expression of vimentin and cytokeratin as prognostic factor of metastases in experimental uveal melanoma
MORILLA A, CAISSIE AL, LOPEZ R, ORDOÑEZ JL, BLANCO G, ALMARAZ A, SAORNIL MA, BURNIER MN—Valladolid, Montreal

209 Metastatic orbital leiomyosarcoma: a case report with CT scan, MRI and Ultrasound findings
VOROS GM, RESSINIOTIS T, OWEN RI, NEOH C, STRONG NP—Newcastle Upon Tyne, Sunderland

210 Distance thermography in diagnostics of orbital diseases
PANTEEVA OG—Moscow

211 Molecular diagnosis of human adenovirus C and D and phylogenetic relationships based on the sequencing of the hexon gene
FERRER RODRIGUEZ C, MASCIOPINTO F, ALIO JL—Alicante

212 A ret-cam imaging study of macular retinoblastoma pre and post treatment
HADJISTILIANOU T, MARTONE G, DE FRANCESCO S, CAPOROSSI ALDO—Siena

213 Optical Coherence Tomographic (OCT) findings in case of subfoveal choroidal metastasis
PICCIRILLO V, PESCE G, SCORCIA V, BRUZZICHESSI D, CARNOVALE-SCALZO G, SCORCIA G—Catanzaro, Italy

214 Microsurgical Biopsy of Intraocular Tumors with High Diagnostic Accuracy
ALL-ERICSSON C, KVANTA A, BERGLIN L, SEREGARD S—Stockholm

215 Commissioning applicators for episcleral brachytherapy
MORILLA A, DE FRUTOS-BARAJA JM, SAORNIL-ALVAREZ MA, PÉREZ-CALATAYUD J, LOPEZ-LARA-MARTÍN F—Valladolid, Valencia

216 Glaucoma and optic nerve drusen
KAWA P, NOWOMIEJSKA K, BIALEK M, HASZCZ D, CZOP DC, MANKOWSKA A, KRUKOWSKI J, ZAGÓRSKI Z—Lublin
rf

217 Doppler Velocities in Retrobulbar Arteries in Normal Pregnancy and Postpartum. A Longitudinal Study
VIGANDER K, TAKSERMAN A, HAUGEN G, KERTY E—Oslo
rf

218 Influence of papilloedema on globe shape
MADILL SA, CONNOR S—London
rf

219 Pupillometry reveals increased inter-eye pupil escape ratio in the eye with a subretinal membrane
ZAIDI FH, MOSELEY MJ—London
rf

220 Eye velocities during static fixation in patients with central scotoma
MACEDO AF, GOMES AOS, NASCIMENTO SMC—Braga, Porto
rf

221 Dural carotid-cavernous fistulas: evolution of the therapeutic strategy from 1992 to 2004. About 9 cases.
VINH VV, LEFOURNIER VL, BERNAL FB, VASDEV ASHOK, BESSOU PB, MOUILLON MM, ROMANET JPR—Grenoble

222 Retained orbital wooden foreign body in children
EL SHEHA H, EL TOKHY E, TSE DT—Cairo, Miami

223 Compressive optic neuropathy in patients with Thyroid Associated Ophthalmopathy (TAO)
CARNOVALE SCALZO G, PAOLA A, LABONIA AF, BRUZZICHESSI D, COSTANTE G, SCORCIA V, SCORCIA G—Catanzaro, Italy

224 Thyroid-Associated Eye Disease (TAED) from Ophthalmologist's point of view
PANTEEVA OG—Moscow

225 Teletransmitted stereoscopic video images in oculoplastic surgery
BERGUA A, MARDIN C, HOLBACH L—Erlangen

226 Accommodative convergence measurement in strabismus using a oculomotor register system by infrared
VIDAL LÓPEZ J—Spain

227 The AC/A ratio in University Students in Portugal
QUEIROSA A, JORGE J, FERNANDES P, ALMEIDA JB, PARAFITA MA—Braga, Santiago de Compostela

228 The Frisby-Davis 2 (FD2) distance stereotest in evaluation of exotropia
HOLMES J. M., LESKE D. A.—Rochester, MN

229 Homonymous hemianopia due to paradoxical embolus in a young adult with interatrial septal defects and cystic fibrosis
KALHORO A, MATAFTSI A, MEARZA A, BRECKER S—Kingston-Upon-Thames, London

230 The incidence of visual field defects following selective amygdalohippocampectomy
KIRCHER K, NOVAK K, PATARAIA E, MARSCHALEK J, BAUMGARTNER C, CZECH T, REITNER A—Vienna

231 Anterior ischemic neuropathy secondary to interferon alpha treatment: a case report
BASSIME L, BARLET T, KOCH P, MULS V, WILLERMAIN F—Brussels

232 Local retinal venous reaction to moderate artificial IOP increase in normals and glaucoma patients
KOTLIAR K, NAGEL E, VILSER W, LANZL I—Munich, Rudolstadt, Ilmenau
rf

233 The assessment of conjunctival hyperemia with latanoprost 0.005% versus travoprost 0.004% therapy
SIEGEL LI, SAROLI TL, JENKINS JN, STEWART WC, PRZYDRYGA JT—Southfield, MI, Charleston, SC, Fort Worth, TX
rf


234 Volume of hypotensive eyedrops: Potential influence factors
ANTON LOPEZ AAL, MARTIN MARTIN BMM, BLAZQUEZ ARAUZO FBA—Valladolid
rf

235 Dynamic autoregulation in the eye and brain
KOLODJASCHNA J, BERISHA F, POLSKA E, SCHMETTERER L—Vienna
rf

236 Retinal endothelial cell dysfunction caused by hyperglycemia and oxidative stress
CASTILHO A, SERRA A, LEAL EC, AVELEIRA C, AMBRÓSIO AF—Coimbra
rf

Moderators: Frédéric MOURIAUX, Pinar AYDIN, Werner SPILEERS and Pierre LACHAPPELLE

- 237 Metipranolol is the only ophthalmic beta-blocker to counteract oxidative stress-induced death to cultured human RPE cells
rf WOOD JPM, OSBORNE NN—Oxford
- 238 Expression of Monocarboxylate Transporters in the Rat Retina: Effects of Retinal Degenerations
rf CHIDLOW G, WOOD JPM, GRAHAM M, OSBORNE NN—Oxford, Loughborough
- 239 Aqueous humour formation is inhibited by bradykinin via production of cyclic GMP
rf WILSON WS, ALMALKI W, MARTIN W—Glasgow
- 240 Non-invasive detection of antibiotics in the aqueous humor by raman spectroscopy
SIDEROUDI TI, PHARMAKAKIS N, PAPATHEODOROU GN, VOYIATZIS GA—Rio-Patras
- 241 Differential Localization of c-Myc in Retinal Pigment Epithelial Cells.
KOTHARY PC, BANSAL A, ZIERENBERG A, DEL MONTE MA—Ann Arbor
- 242 Transscleral Transport of the Triamcinolone Acetonide
MORA P, EPERON S, FELT-BAEYENS O, GURNY R, SAGODIRA S, BRETON P, GUEX-CROSIER Y—Parma, Lausanne, Geneva, Paris
- 243 Potential protective effects of NSAIDs/coxibs/ASA in oxidatively stressed human lens epithelial cells and intact mouse lenses in culture
PETERSEN A, ZETTERBERG M, SJÖSTRAND J, PÅLSSON AZ, KARLSSON J-O—Göteborg
- 244 Method for Functional Imaging of the Reaction of Retinal Vessels to Provocation with Flicker Observation Light
KASSNER C, FINK A, NAGEL E, HENNING G, VILSER W—Ilmenau, Rudolstadt, Jena
- 245 Intraocular pressure lowering effect after Nd-YAG laser posterior capsulotomy: 0.2% brimonidine tartrate versus 0.15% brimonidine-Purite
SEONG GJ, LEE HK, LEE ES, KIM CY, HONG YJ—Seoul
- 246 Nitric oxid formation in the eye of pregnant and virgine autoimmune MRL/lpr mice
GEHL Z, BAKONDI E, KÖKÉNY G, HAMAR P, VIRAG L—Budapest, Debrecen
- 247 The influence of diclofenac ophthalmic solution on the intraocular pressure lowering effect of 0.005% latanoprost in glaucomatous patients
GAVIOLI IG, SEBASTIANI AS, RUSSO AR, CASILLO FC, PARMEGGIANI FP, COSTAGLIOLA CC—Ferrara
- 248 Penetration of oral Ofloxacin into aqueous humour in Cataract surgery
SHIEW M, KARIM A, FIRTH G, FIRTH M, THOMPSON GM, MOSS R, COWDREY G—London, Haywards Heath, W.Sussex
- 249 Retinal arterial vessel response: Comparison of local phenylephrine or liquid tear eye drop application
LANZL I, VILSER W, KOTLIAR K—Munich, Ilmenau
- 250 A Change in the Trace Element Composition of Aqueous Humor in Cataract and Glaucoma as a Possible Derangement Factor of its Metabolic Activity and Hydrodynamics
IOMDINA EN, KISELEVA OA, KACHAN OV, ZHUKOV CR—Moscow
- 251 Effects of cAMP on Short-Circuit Current in Porcine Ciliary Epithelium
NI Y, WU RY, FLAMMER J, HAEFLIGER I.O.—Basel
- 252 The effect of methamphetamine in the rabbit retina after in vitro exposure
RODRIGUES LG, TAVARES MA, OSBORNE NN—Porto, Oxford
- 253 Effects on morphometric parameters in the rat optic nerve following prenatal exposure to methamphetamine
MARTINS ALMEIDA MELO P, PINAZO DURAN MD, TAVARES MA—Porto, Valencia
- 255 Adaptive Optics: a new in vivo in situ non-invasive method toward a high resolution image of retinal photoreceptors
rf SALAMA BS, GLANC MG, GICQUEL JIG, LE GARGASSON JFL—Saint Jean d'Angély, Meudon, Paris
- 256 A method of retaining LogMAR visual acuity data in a "loss-less" fashion
rf ANDERSON OA, FERNANDO FI, DAVIES NP—London
- 257 30 Hz flicker multifocal electroretinography in different macular diseases
LESCH B, FARKAS A, VAMOS R, MODOS K, SALACZ GY—Budapest
- 258 Dominance of the Scotopic on the Photopic Mechanism in Developing Pigmented Rat Retina
YINON U, GURSHUMOV N—Tel-Hashomer
- 259 Recording motion VEPs with an enhanced Roland RETIport system
KNEZY K, MOLNAR FE, NEMETH J—Budapest
- 260 Flash visual evoked potentials after pre- and postnatal exposition on zinc - experimental study
HERBA E, POJDA-WILCZEK D, POJDA SM, PLECH AR, MAKOWIECKA-OBIDZINSKA K—Bytom
- 261 Relationship between crowding effect and background color in disabled readers
VIDAL LOPEZ J—Spain
- 262 Eye-gaze position and contrast in natural environments
PINTO PD, NASCIMENTO SMC, FOSTER DH, AMANO K—Braga, Manchester
- 263 Contrast sensitivity during night driving in subjects older than 50 years
AGUSTIN GONZALO AGUSTIN M, SANCHEZ RAMOS SANCHEZ C, PEREZ CARRASCO PEREZ MJ, PUELL MARIN PUELL C, LANGA MORAGA LANGA A, ELENA TIRADO ELENA MJ, MARTINEZ DE MIGUEL MARTINEZ M—Madrid
- 264 Effect of environmental luminance on contrast sensitivity in vehicle drivers
DEL MORAL MARTÍNEZ MI, SANCHEZ-RAMOS C, PEREZ-CARRASCO MJ, PUELL MC, LANGA-MORAGA A, PÉREZ-PÉREZ JM—Madrid
- 265 Effects of age and the retinal zone stimulated on differential luminance sensitivity in vehicle drivers over 65 years
VILA J, DEL-MORAL I, SANCHEZ-RAMOS C, PUELL C, PEREZ MJ, LANGA A, PÉREZ-PÉREZ JM—Madrid
- 266 Effect of coloured sunglasses on the colours of natural scenes
LINHARES JMM, NASCIMENTO SMC, FOSTER DH, AMANO K—Braga, Manchester
- 267 Computerised Chromatic Contrast Threshold Measurement Study of Digoxin Therapy
GAUBA V, ONG GL, SALEH G, DEWIT D—Brighton, Colchester
- 268 Studies on the perception of very small visual stimuli (microdots)
NILSSON M, MARTIN L—Stockholm
- 269 The influence of the cycloplegic in the objective refraction
JORGE J, QUEIRÓS A, FERNANDES P, ALMEIDA JB, PARAFITA MA—Braga, Santiago de Compostela
- 270 Visual acuity anisotropy in simulated visual impairment
CACHO I, REEVES B C, DICKINSON C M, HARPER R A—Manchester, London
- 271 Variations in ocular biometry in University Students in Portugal
QUEIROS A, JORGE J, FERNANDES P, ALMEIDA JB, PARAFITA MA—Braga, Santiago de Compostela
- 272 Optoelectronic visual aid based on reconfigurable logic for severe peripheral vision loss rehabilitation
VARGAS-MARTÍN F, PELÁEZ-COCA MD, ROS E, DÍAZ J, MOTA S—Murcia, Granada
- 273 Disadvantage of the superotemporal field in normal subjects as revealed by techniques that study the function of the magnocellular pathway
SILVA M, GUERREIRO M, CASTELO-BRANCO M—Coimbra
- 274 The impact of cellular phone usage on ophthalmic equipment
SALEH GM, DE WIT DW, ALLEN RJ, GAUBA V, AZIZ O—Colchester, Leeds, London



ever 2004

Monday 27 September



Gemini I		Ocular biomechanics	08:30 – 10:00
SIS		Konstantin KOTLIAR	
08:30	3111	Possible functional collapse of Schlemm's canal under the influence of ciliary muscle and iris. Biomechanical considerations. KOTLIAR KE, SMOLNIKOV BA, LANZL IM, KOSHITZ IN–Munich, St.Petersburg	
08:45	3112	Membrane models of aqueous humor formation MOISEEVA IM–Moscow	
08:55	3113	Biomechanical Evaluation of the Intraocular Pressure and its Deviations in Glaucomatous Eyes ZASEEVA MV, SVETLOVA OV, SMOLNIKOV BA, KOSHITZ IN–St. Petersburg	
09:05	3114	Age related changes of elastic properties of the sclera in human eyes SVETLOVA OV, ZASEEVA MV, SOURJIKOV AV, SHUKHAEV SV–St. Petersburg	
09:15	3115	Improving Elastic and Tensile Properties of the Sclera by UVA and Riboflavin Treatment IOMDINA EN, WOLLENSAK G, MUKHAMEDJAROW F, SPOERL E–Moscow, Berlin, Dresden	
09:25	3116	Change in optical refraction after scleral buckling - a biomechanical model LANZL IM, BAUER SM, KOTLIAR KE, MAIER M–Munich, St. Petersburg	
09:35	3117	Static analysis of the crystalline lens accommodation ISPOLOVA EA, SMOLNIKOV BA, SVETLOVA OV, KOSHITZ IN–St. Petersburg	
09:45	3118	Quantitative biomechanical estimation of functional ambits in the main and additional mechanisms of eye accommodation KOSHITZ IN, KOTLIAR KE, SVETLOVA OV–St. Petersburg, Munich	

Gemini III		New developments in OCT	08:30 – 10:00
SIS		Marc D DE SMET	
08:30	3121	OCT in daily management: comparison with FA in analysis of leakage in subfoveal CNV. VERBRAAK FD, VAN VELTHOVEN MEJ, SCHLINGEMANN RO, MAGNANI M, DE SMET MD–Amsterdam, Bologna	
08:42	3122	OCT in clinical research in diabetes PEREIRA FIGUEIRA J, BERNARDES R, CUNHA-VAZ J–Coimbra	
08:54	3123	Errors and misinterpretations of OCT examination HAOUCHINE B–Paris	
09:06	3124	Media opacities and their effect on the OCT signal and interpretation VAN VELTHOVEN MEJ, VAN DER LINDEN MH, FABER D, VERBRAAK FD, DE SMET MD–Amsterdam	
09:18	3125	Pattern recognition in multiplanar OCT ROSEN R, PODOLEANU A GH, GARCIA P M, WEITZ R–New York, Canterbury, Toronto	
09:30	3126	Software assisted overlay of OCT C-scans and conventional angiography DE SMET M, VERBRAAK FD, VAN VELTHOVEN MEJ, DE VOS K, POOL CW–Amsterdam	

Pegasus		Contact lenses: Applications and Complications	08:30 – 10:00
SIS		Martin RUBINSTEIN, Hendrika JM VÖLKER-DIEBEN	
08:30	3131	A cross-sectional survey of the medical indications for and performance of Scleral Contact Lens Wear in the Netherlands VISSER ES, VISSER R, VAN LIER HJJ, OTTEN HM–Nijmegen	
08:50	3132	Therapeutic applications of contact lenses JACKSON AJ–Belfast	
09:10	3133	Visual rehabilitation after corneal grafting: what types of contact lenses are chosen? GEERARDS AJM–Rotterdam	
09:30	3134	Contact lens related ulcerations in Belgium. Trends over a seven year period KOPPEN C, VERHELST D–Antwerp	

General Assembly

10:15 – 11:00, Fenix III

EVER General Assembly**Agenda**

1. President's address
2. Minutes of the General Assembly of 2003
3. Report of the General Secretary
4. Report of the Programme Secretary
5. Report of the Treasurer, budget for 2005
6. Results of the elections
7. Presentation of the Board for 2004-2005
8. President Elect and Vice President Elect
9. Honorary Members
10. Report of the Scientific Sections meetings
11. Future congresses
12. Miscellanea

Vega ***Pupil function: new concepts and clinical implications*** 08:30 – 10:00
 SIS Avinoam SAFRAN, John BARBUR

- 08:30 3141 Melanopsin-Containing Retinal Ganglion Cells: Novel Photoreceptors Involved in Pupillary Light Reflex
HATTAR S, LUCAS RJ–Baltimore, Manchester
- 08:50 3142 The Hemifield Pupil Response in Patients with a Unilateral Optic Tract Lesion: Implications for the Tectal RAPD
KAWASAKI A, KARDON R–Lausanne, Iowa City
- 09:10 3143 The fear-inhibited light reflex: The pupil as a test-system in Anxiety research
BITSIOS P–Heraklion
- 09:30 3144 Learning from the pupil - fundamental studies and clinical applications
BARBUR JL, RODRIGUEZ - CARMONA M, HARLOW JA–London

Fenix I ***Free Paper Session: Glaucoma 1*** 08:30 – 10:00
 FP Jost B JONAS, Michael WIEDERHOLT

- 08:30 3151 Expression of matrix metalloproteinases (MMP'S) in the juxtalcalicular tissues in poag ad exfoliation glaucoma (ExG)
UUSITALO H, RONKKO S, REKONEN P, KAARNIRANTA K, OKSALA E, PUUSTJARVI T, TERASVIRTA M–Kuopio, Finland
- 08:42 3152 Survey of glaucoma treatment in pregnancy
VAIDEANU D, FRASER SG–Sunderland
- 08:54 3153 Adjunctive use of Ginkgo Biloba in patients undergoing glaucoma
RUIZ-LAPUENTE CJ, PLAZAS A, BERENGUER-ANDREU J, GÓMEZ L–Sevilla
- 09:06 3154 A 10 Year Outcome Study following Bilateral YAG laser Peripheral Iridotomy
WRIDE NK, VAIDEANU D, FRASER SG–Sunderland
- 09:18 3155 Standard Deep Sclerectomy with Collagen Implant Compared to a New Method of Very Deep Sclerectomy with Collagen implant: a Randomised Controlled Trial
MANSOURI K, VIET TRAN H, MERMOUD A–Lausanne
- 09:30 3156 Effects of latanoprost 0.005% and the fixed combination dorzolamide/timolol on IOP and retrobulbar hemodynamics in glaucoma patients
rf MARTÍNEZ-GARCÍA AMG, SANCHEZ-SALORIO MSS, GARCÍA-FEIJOO JGF–Santiago de Compostela, Madrid
- 09:36 3157 The rabbit's IOP after instillation of the amino acid L-arginin.HCl and antiglaucomatics misture
rf OLAH Z, VESELOVSKY J, GRESSNEROVA S, VESELA A–Bratislava
- 09:42 3158 Clinical experience with the Ahmed Valve implant in a non-tertiary ophthalmic unit
rf KALHORO A, MATAFTSI A, ATTENBOROUGH M, MEARZA A, BIDGOOD P, MCNIECE R, GILLESPIE I–Kingston-Upon-Thames
- 09:48 3159 Evaluation of preoperative factors associated with success of mitomycin C needling revision for failed filtration blebs: a prospective study
rf GUTIERREZ CG, TEUS MT–Alcala de Henares

Fenix III ***Ocular endothelins: A role in ocular disease?*** 08:30 – 10:00
 SIS Thomas YORIO

- 08:30 3161 Endothelin-1 is a major regulator of ocular blood flow in humans
SCHMETTERER L–Vienna
- 08:48 3162 The Role of Endothelin 1: Elevation in retinal vascular abnormalities of diabetes
KING G–Boston, MA
- 09:06 3163 Endothelin system in human eye: overexpression of ET-1 in the anterior segment of patients with primary open-angle glaucoma
FERNANDEZ DURANGO R–Madrid
- 09:24 3164 Endothelin-1 induced optic nerve damage
CHAUHAN BC–Halifax
- 09:42 3165 Endothelin and glaucoma
YORIO T, PRASANNA G, KRISHNAMOORTHY R–Forth Worth

Gemini I	Endothelin-1 in glaucoma and other ocular diseases		11:00 – 12:30
SIS	Timo HAUFSCCHILD, Selim ORGUL		
11:00	3211	Endothelin-1, trigger or active component in ocular diseases SCHMETTERER L–Vienna	
11:15	3212	Metabolism of endothelin-1 (ET-1), principles of measurement in the plasma and prevalence in ocular diseases HAUFSCCHILD T–Basel	
11:30	3213	Endothelin-1 and exfoliative glaucoma HOLLÓ G–Budapest	
11:45	3214	Endothelin-1 in progressive glaucoma ORGUL S, EMRE M, HAUFSCCHILD T, SHAW SG, FLAMMER J–Basel, Berne	
12:00	3215	Endothelin-1 plasma levels in patients with Central Serous Chorioretinopathy PRUENTE CH, HAUFSCCHILD T, FLAMMER J–Basel	

Gemini III	EUREYE		11:00 – 12:30
SIS	Astrid FLETCHER		
11:00	3221	Prevalence of age related maculopathy and macular degeneration AUGOOD C–London	
11:12	3222	Antioxidants and risk of ARM YOUNG IS–Belfast	
11:24	3223	Solar radiation and age related macular degeneration FLETCHER AE–London	
11:36	3224	Vision-related quality of life in the EUREYE study CHAKRAVARTHY U–Belfast	
11:48	3225	Smoking and risk of AMD SOUBRANE G–Creteil	
12:00	3226	Cardiovascular risk factors and type of AMD TOPOUSIS F–Thessaloniki	
12:12	3227	Prevalence of visual impairment in the EUREYE study SELAND J–Bergen	

Pegasus	Molecular mechanisms of angiogenesis and lymphangiogenesis in the eye		11:00 – 12:30
SIS	Hansjürgen T AGOSTINI		
11:00	3231	Molecular mechanisms of lymphangiogenesis: the cornea as a model system CURSIEFEN C–Erlangen	
11:15	3232	Diabetic macular edema - molecular pathways JOUSSEN J–Köln	
11:30	3233	Ephrin/Ephs in proliferative retinopathy - lessons from a mouse model AGOSTINI HT–Freiburg	
11:45	3234	VEGF/VEGFR interactions in ocular development, physiology and disease SCHLINGEMANN RO, WITMER AN–Amsterdam	
12:00	3235	Regulation of angiogenesis and vascular homeostasis through the Angiopoietin/Tie system AUGUSTIN HG–Freiburg	

Vega	<i>Ophthalmodynamometry: The PAST and the FUTURE</i>	11:00 – 12:30
SIS	Pinar AYDIN	

Sponsored by the Meditron GmbH

11:00	3241	Introduction AYDIN P–Ankara
11:10	3242	Ophthalmodynamometry: From Bailliart to the contact lens dynamometer STODTMEISTER R–Pirmasens
11:30	3243	Intracranial pressure measured by venous dynamometry of the central retinal vein MEYER-SCHWICKERATH RMS–Bocholt
11:50	3244	Clinical experience with modified ophthalmodynamometry JONAS JB–Heidelberg
12:10	3245	Quantitative evaluation of Ophthalmodynamometry in a rabbit model REITSAMER HA–Salzburg

Fenix I	<i>Advances in colour vision assessment and its clinical applications</i>	11:00 – 12:30
SIS	John BARBUR	

11:00	3251	The role of colour vision testing in the diagnosis and management of acquired degenerative eye diseases ARDEN GB, WOLF JE, BERNINGER T–London, Munich
11:15	3252	The use of central and peripheral colour contrast threshold in ophthalmological practice SPILEERS W–Leuven
11:30	3253	Colour vision and cone driven signals: insights from multifocal ERG and VEP JAEGLE H–Tuebingen
11:45	3254	Methods for detection of significant changes in chromatic sensitivity BARBUR JL–London
12:00	3255	Evaluating color vision at the earliest of ages KNOBLAUCH K–Bron
12:15	3256	Long-term renormalization of chromatic mechanisms associated with aging, disease and following cataract surgery WERNER J, DELAHUNT PB, HARDY JL–Sacramento, CA

Fenix III	<i>Accommodation in the intact eye</i>	11:00 – 12:30
SIS	Gijs FJM VRENSSEN, Robert A WEALE	



11:00	3261	Ultrasonographic studies of ciliary muscle related to accommodation in the human eye GUTHOFF R, STACHS O, MARTIN H–Rostock
11:15	3262	Experimental studies of accommodation in monkeys GLASSER A–Houston, TX
11:30	3263	In vivo studies of the human lens using corrected Scheimpflug imaging DUBBELMAN M–Amsterdam
11:45	3264	To investigate the changes in position of the lens surfaces during accommodation VAN DER HEIJDE RGL–Amsterdam
12:00	3265	We were not born to read WEALE R–London
12:15	3266	Lenticular accommodation in relation to ametropia: the chick model CHOH V, SIVAK JG–Berkeley, CA, Waterloo, Ontario

Gemini I **Neuroprotection in the visual system** 14:00 – 15:30
 SIS Manuel VIDAL-SANZ, Neville OSBORNE



14:00	3311	Supplementation of zinc may benefit glaucoma patients OSBORNE NN–Oxford
14:15	3312	Neuroprotection of Cones in Retinitis pigmentosa SAHEL JA, LEVEILLARD T–Paris
14:30	3313	Retinal ischemia alters axonal transport in retinal ganglion cells: neuroprotective effects of brimonidine. VIDAL-SANZ M, MAYOR S, LAFUENTE MP, GARCIA A, BERNAL JM, VILLEGAS-PEREZ MP–Murcia
14:45	3314	Evidence for neuroprotection in experimental ocular hypertension WHEELER LA, WOLDEMUSSIE E, HARE WA–Irvine, CA
15:00	3315	Neuroprotection in randomized clinical glaucoma trials GANDOLFI S–Parma

Gemini III **Ocular blood flow in AMD** 14:00 – 15:30
 SIS Charles RIVA, Leopold SCHMETTERER



14:00	3321	Choroidal blood flow regulation in the healthy human eye. A review RIVA CE–Lausanne
14:12	3322	Sub-foveal Choroidal Blood Flow in Healthy Individuals Before and After Timolol Maleate Administration FALSINI B, GEISER M, GALAN ME, RIVA CE–Rome, Sion
14:24	3323	Choroidal blood flow in AMD GRUNWALD JE, METELITSINA T, DUPONT J–Philadelphia
14:36	3324	Limitations and possibilities in assessing choroidal perfusion in AMD patients with currently available technology SCHMETTERER L–Vienna
14:48	3325	Choroidal circulatory failure in AMD POURNARAS CJ, RIVA CE, LOGEAN E–Geneva, Sion
15:00	3326	Choroidal circulatory changes in central serous chorioretinopathy PETROPOULOS IK, RIVA CE, STANGOS AAN, PETRIG BL, POURNARAS CJ–Geneva, Sion
15:12	3327	Choroidal blood flow regulation in patients with CSC WEIGERT G, MAAR N, TITTL M, LUKSCH A, STUR M, SCHMETTERER L–Vienna

Pegasus **Free Paper Session: Corneal Grafting** 14:00 – 15:30
 FP Reza DANA, Uwe PLEYER

14:00	3331	Corneal Hemangiogenesis And Lymphangiogenesis Immediately Following Penetrating Keratoplasty Are Triggered By Surgery And Wound Healing Rather Than Alloimmunity MARUYAMA K, CURSIEFEN C, JACKSON DG, DANA R, STREILEIN JS, STREILEIN JW–Boston, Erlangen, Oxford
14:12	3332	Inhibition of Hem- and Lymphangiogenesis after Normal-Risk Corneal Transplantation Improves Graft Survival CURSIEFEN C, DANA MR, WIEGAND S, KRUSE FE, STREILEIN JW–Erlangen, Boston, Tarrytown, NY
14:24	3333	Effect of different immunosuppressive treatment strategies on natural killer cell involvement in corneal allograft rejection CLAERHOUT I, KESTELYN PH, BEELE H, LECLERCQ G–Ghent
14:36	3334	Gene transfer of AdCTLA4-Ig prolongs experimental corneal allograft survival PLEYER UP, YANG J, GONG N., VOGT K, HEMPEL M, ANEGON L, RITTER T–Berlin, Nantes
14:48	3335	Descemet's membrane retained during penetrating keratoplasty JASTANEIAH SJ–Riyadh
15:00	3336	Artificial Cornea- Rapport of Human Corneal Cells and Animal Tests GAN L, FAGERHOLM P, LIU Y, CARLSSON D, GRIFFITH M–Linköping, Ottawa
15:12	3337 <i>rf</i>	Topical hydro-soluble prodrug of cyclosporin A to prevent corneal graft rejection BOURGES JL, VALAMANESH F, AGLA EK, LALLEMAND F, GURNY R, JEAN-MAURICE D, BESSEGHIR K, BEHAR-COHEN FF–Paris, Lausanne, Geneva
15:18	3338 <i>rf</i>	The role of T Helper 1 (Th1) and Th2 cytokines in corneal graft rejection HOLAN V, VITOVA A, PINDJAKOVA J, KRULOVA M, ZAJICOVA A, FILIPEC M–Prague
15:24	3339 <i>rf</i>	Roles of Thrombospondin-1 and -2 in Maintaining Corneal Angiogenic Privilege CURSIEFEN C, DANA MR, LAWLER J, STREILEIN JW–Erlangen, Boston

PC-Room **Using Microsoft Word II** 14:00 – 15:30
 PC-Course Maarten TRUYENS



Generating a table of content or index • Why does my Word-document get corrupted? • Using document sections • General pitfalls

Vega	Visual function in pediatric neuro-ophthalmology		14:00 – 15:30
SIS	Pinar AYDIN		

14:00	3341	Introduction AYDIN P–Ankara
14:10	3342	Ocular morphology and visual function in children born preterm and in children born small for gestational age HELLSTROM A–Göteborg
14:30	3343	Optic disc appearance and visual function in preterm children with periventricular white matter damage JACOBSON L–Stockholm
14:50	3344	Computerized perimetry in children MARTIN L–Stockholm
15:10	3345	Visual impairment in children with motor handicaps HYVARINEN L–Helsinki

Fenix I	Free Paper Session: Genetics & Epidemiology		14:00 – 15:30
FP	Jochen GRAW, Astrid FLETCHER		

14:00	3351	Mouse models for retinal dysfunction DALKE C, FAVOR J, PRETSCH W, SOEWARTO D, FUCHS H., HRABE DE ANGELIS M, GRAW J–Neuherberg
14:12	3352	Association between sunlight exposure and pterygium prevalence in indigenous populations of the Brazilian Amazonian rain forest PAULA JS, THORN F, CRUZ AAV–Ribeirão Preto, São Paulo, Boston, MA
14:24	3353	Vision impairment and its causes in Northern India JOHN N, MURTHY GVS, GUPTA SJ, PRICE GM, CHAKRAVARTHY U, MARAINI G, CAMPARINI M, FLETCHER AE–London, New Delhi, Belfast, Parma
14:36	3354	Disposable camera viewfinders as visual field expanders for tunnel vision VARGAS-MARTIN F–Murcia
14:48	3355 <i>rf</i>	Degradation of GLUT1 by the ubiquitin proteasome pathway (UPP) on retinal endothelial cells FERNANDES R, CARVALHO AL, MURTA J, FERNANDES A, FARO C, PEREIRA P–Coimbra
14:54	3356 <i>rf</i>	Detection of basic fibroblast growth factor after scleral implantation of orbital adipose tissue in a pig's eye PINNA A, CARTA A, MANUNTA L, CAREDDU GM, MADEDDU P, CARTA F–Sassari, Italy, Parma, Italy
15:00	3357 <i>rf</i>	Cumulative incidence of visual impairment and competing risks in childhood-onset type 1 diabetes VIRTAMO T, KIVELÄ T, YKI-JÄRVINEN H, STENMAN UH, HARJUTSALO V, TUOMILEHTO J, LAATIKAINEN L, SUMMANEN P–Helsinki

Fenix III	Accommodative IOL part 1		14:00 – 15:30
SIS	Rafael I. BARRAQUER, Ralph MICHAEL		

14:00	3361	Restoring accommodation in pseudophakic eyes TASSIGNON MJ–Antwerp
14:18	3362	Hydrogels as potential lens replacement material RAVI N–St. Louis, Missouri
14:36	3363	Model of IOL with changeable optical power SERGIENKO N–Kiev, Ukraine
14:54	3364	Optical and Mechanical Design for Human Implantation of the Sarfarazi Elliptical Accommodating Intraocular Lens (EAIOL) SARFARAZI FM–Carlsbad, CA
15:12	3365	What is there to be learned about accommodation and presbyopia from in vitro mechanical stretching studies? GLASSER A–Houston, TX

Keynote Lecture

15:45 – 16:30, Fenix III

Characterization of Diabetic Retinopathy Phenotypes. Perspectives for improved management.

Jose CUNHA-VAZ—Coimbra

Introduction by Jean-Jacques DE LAEY

Poster session

16:30 – 17:30, Neptuno

Molecular Biology, epidemiology, cornea 2, cornea 3, glaucoma, refractive surgery

Philippe KESTELYN, Gabor HOLLÓ, Jonathan JACKSON, Jost JONAS

Gemini I	Free Paper Session: Glaucoma 2	17:30 – 19:06
FP	Leopold SCHMETTERER	

17:30	3411	Detection of Glaucomatous eyes using Automated perimetry, Scanning laser ophthalmoscopy of the optic disk or scanning laser polarimetry of the RNFL MILANO G, MACERI C, TISO C, SCATASSI I, ROSSI GCM–Pavia
17:42	3412	Optic disc edema leads to non-reliable OCT retinal nerve fiber layer thickness measurements MENKE MN, FEKE GT, TREMPER CL–Boston, MA
17:54	3413	Early morphological changes in an ocular hypertensive monkey model of claucoma as evidenced with ultrahigh-resolution Optical Coherence Tomography, Scanning Laser Polarimetry and Scanning Laser Tomography DOELEMAYER A, POLSKA E, SCHMETTERER L, DREXLER W, LAMBROU GN–Basel, Vienna
18:06	3414	Relationship between OCT nerve fiber layer thickness and visual field sensitivity level in corresponding areas UNGARO N, TARDINI MG, GANDOLFI S–Parma
18:18	3415	Relationship of Intraocular Pressure and Perfusion Pressure on Progression of Glaucoma WIEDERHOLT M, ERB C–Berlin, Hannover
18:30	3416	Dynamic contour tonometry (DCT): A comparison with Goldman applanatory tonometry with respect to central corneal thickness KAMPPETER BA, DEGENRING RF, JONAS JB–Heidelberg
18:42	3417 <i>rf</i>	Comparison of anterior and posterior corneal curvatures (Orbscan II) in normal and glaucoma patients HERNANDEZ VJL, TEUS MA, MARINA C, GIL R, SÁNCHEZ JM–Madrid
18:48	3418 <i>rf</i>	Central corneal thickness correlated with glaucoma damage and rate of progression JONAS JB, STROUX A, VELTEN I, JUENEMANN A, MARTUS P, BUDDE WM–Heidelberg
18:54	3419 <i>rf</i>	Chronic ocular hypertension alters retrograde axoplasmic transport in adult rats MAYOR - TORROGLOSA S, VILLEGAS-PÉREZ MP, SALAZAR JJ, RAMÍREZ JM, TRIVIÑO A, RAMÍREZ AI, COLL L, VIDAL-SANZ M–Murcia, Madrid
19:00	341a <i>rf</i>	Chronic ocular hypertension induced degeneration of retinotectal afferents: long term neuroprotection with topical brimonidine MAYOR - TORROGLOSA S, WOLDEMUSSIE E, GARCÍA A, RUIZ G, BERNAL JM, WHEELER LA, VIDAL-SANZ M–Murcia, Irvine, California

Gemini III	Health Economics	17:30 – 19:00
SIS	Andrew SMITH	

17:30	3421	Health Economics for the European Vision Research Community SMITH AF–Oxford
-------	------	--

Pegasus	Free Paper Session: Refractive Surgery	17:30 – 19:00
FP	Philippe KESTELYN	

17:30	3431	Anatomical and geometric model for biomechanical corneal flattening in Lasik: The flap and stromal ablation in myopia surgery VELARDE JI, LLORCA F, FERNANDEZ DEL COTERO JN–Santander
17:42	3432	LASIK induced Keratectasia JASTANEIAH SJ, RAJHI AR–Riyadh
17:54	3433	Effect of lasik to correct high compound myopic astigmatism on visual acuity GIL R, ARRANZ E, SÁNCHEZ JM, HERNANDEZ VERDEJO JL, TEUS MA–Madrid
18:06	3434	Contrast sensitivity function and low contrast visual acuity in low to moderate myopic patients after LASIK GIL R, TEUS MA, HERNANDEZ VERDEJO JL, ÁLVAREZ MT, MARINA C–Madrid
18:18	3435	What can we learn from failures in refractive surgery? MÜLLER LJ, NIEUWENDAAL CP–Amsterdam
18:30	3436 <i>rf</i>	Risk Factors for Laser In Situ Keratomileusis (LASIK) BEHNDIG AB, JONSSON M–Umeå
18:36	3437 <i>rf</i>	Therapeutic Applications of Contact Lenses in Myopia Control MAHOMED A, PUNYAMOONWONGSA P, TIGHE B–CEAC
18:42	3438 <i>rf</i>	Comparison of early and middle-term microscopic morphological corneal response after PRK, LASEK and alcohol-free LASEK NUBILE M, LANZINI M, COSTANTINO O, MASTROPASQUA L–Chieti, Italy

Vega	Novel ophthalmic technologies II		17:30 – 19:00
SIS	Tom MISSOTTEN		

17:30	3441	Improved retinal imaging by combining a series of OCT scans SANDER B, MARTINI JøRGENSEN T–Copenhagen, Roskilde
17:45	3442	Avenues opened by en-face OCT in imaging the eye PODOLEANU A, ROSA CC, DOBRE GM, CUCU R, JACKSON DA, ROSEN RB, ROGERS JA–Canterbury, New York, Toronto
18:00	3443	Recent developments in Ultrahigh resolution OCT DREXLER W–Vienna
18:15	3444	Ultra-high resolution video rate in vivo retinal imaging and Doppler velocimetry with Spectral Domain Optical Coherence Tomography DE BOER JF–Boston
18:30	3445	Miniaturized Fundus Cameras NIEDERER P–Zurich
18:45	3446	Selective Retina Therapy (SRT): Technics, Methods and First Clinical Results BRINKMANN R, THEISEN-KUNDE D, ELSNER H, PÖRKSEN E, HAMILTON P, ROIDER J, BIRNGRUBER R–Lübeck, London, Kiel

Fenix I	International ophthalmology in developing countries		17:30 – 19:00
SIS	Alexander BIALASIEWICZ		

Fenix III	Accommodative IOL part 2		17:30 – 19:00
SIS	Ralph MICHAEL, Rafael I. BARRAQUER		

17:30	3461	Manual lens stretching apparatuses for optical properties analysis of natural lens, iols and refilled lens capsule (phaco-ersatz) ACOSTA AC, LAMAR PD, LEE W, DENHAM DB, ABRI A, NOSE I, ZIEBARTH N, BORJA D, OROZCO M, MANN S F, HO A, PAREL JM–Miami, FL, Sydney
17:48	3462	In vivo experiments of polymer refilling of the capsular bag for presbyopia KOOPMANS SA, TERWEE T, KOOIJMAN AC, GLASSER A, WENDT M–Groningen, Houston, TX
18:06	3463	Phaco-Ersatz 2004 update: Ex-vivo pre-post lens capsule refilling optomechanical accommodative evaluation. PAREL JM, LAMAR PD, ACOSTA AC, BILLOTTE CHRISTIAN, FERNANDEZ V, ABRI A, DENHAM DB, LEE W, ZIEBARTH N, BORJA D, OROZCO M, MANN S F, HO A, WATLING T, HUGHES T, MANOR B, SWEENEY D, AUGUSTEYN R, HOLDEN B–Miami, Vienna, Caen, Sydney, Melbourne
18:24	3464	Computer controlled lens stretching device BARRAQUER R, MICHAEL R, CARRETTIE R–Barcelona

- 301 **Angiogenesis in the eye after an intravitreal injection of adenovirus vegf-a**
KINNUNEN K, RISSANEN T, UUSITALO H, YLA-HERTTUALA S—Kuopio
- 302 **Measuring the cone contribution to the ERG b-wave to assess function and predict anatomical rescue in RCS rats**
PINILLA I, SAUVE Y, LUND RD—Salt Lake City
- 303 **Cone function in P23H rats**
SAUVE Y, PINILLA I, LUND RD—Salt Lake City
- 304 **Subretinal injection of human retinal pigment epithelial cells can preserve rod and cone function in a model of retinal degeneration, the RCS rat**
SAUVE Y, PINILLA I, LU B, WANG S, LUND RD—Salt Lake City
- 305 **Leber congenital amaurosis - a case report**
VA'MOS R, FARKAS Á, SALACZ G—Budapest
- 306 **The Prevalence of Refractive Errors in University Students in Portugal**
JORGE J, FERNANDES P, QUEIRÓS A, ALMEIDA JB, PARAFITA MA—Braga, Santiago Compostela
- 307 **Five-year mortality rate following blind/partially sighted registration in Sunderland, UK**
SETHU MADHAVAN A, VAIDEANU D, FRASER S—Newcastle Upon Tyne, Sunderland
- 308 **The prevalence of open angle glaucoma on the west coast of Iceland**
LINDEN C, JÓHANNESSON G, GUOMUNDSDÓTTIR GJ—Umeå, Sweden, Akranes, Iceland
- 309 **Vision screening of secondary school children in Poland**
SALOMON E, JANOCHA A, URBAN E—Wrocław
- 310 **Clinical outcome of endonasal KTP laser assisted dacryocystorhinostomy**
RESSINIOTIS T, VOROS GM, KOSTAKIS VT, NEOH C—Newcastle upon Tyne
- 311 **Acute dacryoadenitis and the prominent role of non-steroidal anti-inflammatories.**
DE WIT DW, ROSE GE—London
- 312 **3D tele-ophthalmology adds new clinically useful informations the the images of the anterior segment of the eye**
LIBONDI T, COLONNA G, CRICELLI R, GRIFFO E—Napoli
- 313 **Paracetamol induced hepatic injury leading to bilateral vitreous haemorrhage**
ALLEN RJ, SALEH GM, RACHAPALLI S, DE WIT DW, SHELDRIK J—Colchester, London
- 314 **Degradation of GLUT1 by the ubiquitin proteasome pathway (UPP) on retinal endothelial cells**
FERNANDES R, CARVALHO AL, MURTA J, FERNANDES A, FARO C, PEREIRA P—Coimbra
- 315 **Detection of basic fibroblast growth factor after scleral implantation of orbital adipose tissue in a pig's eye**
PINNA A, CARTA A, MANUNTA L, CAREDDU GM, MADEDDU P, CARTA F—Sassari, Italy, Parma, Italy
- 316 **Causes of blindness in equatorial rain forest, Democratic Republic of Congo**
KAIMBO WA KAIMBO D, MISSOTTEN L—Kinshasa, Leuven
- 317 **Cumulative incidence of visual impairment and competing risks in childhood-onset type 1 diabetes**
VIRTAMO T, KIVELÄ T, YKI-JÄRVINEN H, STENMAN UH, HARJUTSALO V, TUOMILEHTO J, LAATIKAINEN L, SUMMANEN P—Helsinki
- 318 **Ocular & Dermal Hydration: The Role of Hydrogels in the Control of Moisturisation**
TIGHE B, BAHIA R—CEAC
- 319 **Correlation of Schirmer test score and tear break up time with Ocular surface staining in Dry Eye disease**
SUNDARAM V, EVERY S, BRON AJ, SAMARASINGHE S, PRABHAKARAN E, VATHESATOGIT C—Oxford
- 320 **Ultrastructural findings and BIG-H3 expression in a new syndrome of corneal lattice dystrophy with myelopathy**
AKHTAR S, TALBOT K, BRON A, DONAGHY M—Cardiff, Oxford
- 321 **Differentially altered proteins in keratoconus**
NIELSEN KN, VORUM HV, PER FAGERHOLM PF, BIRKENKAMP-DEMTRÖDER KBD, HONORÉ BH, ORNTOFT TFQ, EHLERS NE—Aarhus, Linköping
- 322 **Prophylactic and therapeutic efficacy of active and passive immunization using 20-kDa against *S. epidermidis* keratitis**
GEORGAKOPOULOS C, EXARCHOU A, GARTAGANIS S, ANASTASSIOU E, DIMITRAKOPOULOS G, HJERPE A, THEOCHARIS A, KARAMANOS N—Patras, Greece, Stockholm
- 323 **Study of metastatic cancer cell lines survival in corneal organ culture conditions**
DEB N, HERRAG S, MANISSOLLE C, GRESTA P, CAMPOS L, PEOC'H M, GAIN P, THURET G—Saint-Etienne
- 324 **Application of Multivariate Analysis on High-Resolution Magic Angle Spinning (HR-MAS) 1H NMR Spectra of Rabbit Cornea.**
TESSEM MB, BATHEN TF, CEJKOVA J, MIDELFART A—Trondheim, Prague
- 325 **Ocular manifestations in nephropathy cystinosis: a long-term study in children treated with cysteamine**
PINELLO L, MONTINI G, CERMAKOVA I, ZACCHELLO G—Padua
- 326 **Sub-conjunctival haemorrhage during subtenon injection: reduced rates with localised conjunctival cautery**
GAUBA V, SALEH G, DEWIT D, CHUNG A—Brighton, Colchester, Leeds
- 327 **A refined measure of the economic and quality life impact of seasonal allergic conjunctivitis in Spain**
SMITH AF—Hemel Hempstead, UK
- 328 **Photokeratitis secondary to exposure to UV light from fish tank water purification systems**
DWARIKA D, BHOLA RM—Birmingham, Sheffield
- 329 **Evaluation of Corneal Curvature and Thickness in Posterior Microphthalmos**
NOWILATY SR, AL-JISHI Z, AL-HAMAD A—Riyadh
- 330 **The Development of A Disposable Ophthalmic Barrier System To Prevent Cross-Infection From Contact Ophthalmic Devices - An Update**
FRANKLIN VJ, HENLEY C, TIGHE B, KERR J, GEE H, FLANAGAN J—CEAC, Croydon, Wiltshire, Waterloo
- 331 **Biglycan affects adhesion of keratocytes**
KOULIKOVSKA M, PODSKOCHY A, FAGERHOLM P—Linköping
- 332 **Rat Contact Lens Model: Early Analysis of Pseudomonas aeruginosa Corneal Infection**
SZLITER EA, BARRETT RP, GABRIEL MM, HAZLETT LD—Detroit, Duluth
- 333 **Topographical Changes in Anterior Corneal Curvature After LASIK**
GONZALEZ-MEIJOME JM, DIAZ-REY A, SAÑUDO F, QUEIRÓS A, ALMEIDA JB, PARAFITA MA—Braga, Valencia, Santiago de Compostela
- 334 **A case of the incidental trauma lasik flap**
SCORCIA V, ROTONDO E, PICCIRILLO V, BRUZZICHESSI D, CARNOVALE-SCALZO G, SCORCIA G—Catanzaro
- 335 **Second Generation Wavelets for Characterisation of Corneal Topography Height Data**
LANGENBUCHER A, PRAUSE A, SEITZ B—Erlangen
- 336 **Wavefront analysis of spherical and spherical astigmatic hyperopia with the MEL 80 excimer laser**
NAGY Z Z, SZABÓ V, SÜVEGES I—Budapest
- 337 **Rotary scanning system for elevation topography and pachymetry**
FRANCO S, ALMEIDA JB, PARAFITA M—Braga, Santiago de Compostela
- 338 **Relationship between central corneal pachymetry and other ocular and general parameters in normal population**
HERNANDEZ VJL, ROMAN JM, MARTÍN B, SÁNCHEZ JM, TEUS MA—Madrid
- 339 **Photodisruption Characteristics of Femtosecond Laser Effects in Corneal Tissue**
VOSSMERBAEUMER U, JONAS JB—Mannheim
- 340 **Risk Factors for Laser In Situ Keratomileusis (LASIK)**
BEHNDIG AB, JONSSON M—Umeå
- 341 **Adenovirus-mediated gene transfer of viral interleukin-10 (vIL-10) prolongs survival of corneal allografts and moderates rejection process**
GONG N, YANG J, DANNOWSKI H, SCHMIDT N, VOGT K, VOLK HD, PLEYER U, RITTER T—Berlin
- 342 **Production of nitric oxide during the corneal rat-to-mouse xenograft rejection and the effect of anti-CD4 or anti-CD8 treatment**
VITOVA A, PINDJAKOVA J, KRULOVA M, ZAJICOVA A, FILIPEC M, HOLAN V—Prague
- 343 **Assessment of the human corneal endothelium. In vivo noncontact specular microscope topcon SP2000 versus ex vivo sambacornea analyser**
THURET G, MANISSOLLE C, GAVET Y, CAMPOS-GUYOTAT L, GAIN P—Saint-Etienne
- 344 **Endothelial cell count and morphometry by the tri image analyser sambacornea: multicentric validation**
GAIN P, GAVET Y, MANISSOLLE C, HERRAG S, DEB N, MEULLE A, ACQUART S, GARRAUD O, EGELHOFFER H, THURET G—Saint-Etienne, Grenoble
- 345 **Fixed frame technique for endothelial cell count: inherent errors**
GAIN P, GAVET Y, MALASSAGNE F, CAMPOS L, ACQUART S, GARRAUD O, THURET G—Saint-Etienne, Meylan, France
- 346 **Updating of the image analysis methods for specular microscopy: tri image endothelial analysis**
GAVET Y, THURET G, PINOLI JC, GAIN P—Saint-Etienne
- 347 **Pan-caspase inhibitor blocks staurosporine induced human corneal endothelial apoptosis**
HERRAG S, MANISSOLLE C, CAMPOS-GUYOTAT L, GAIN P, THURET G—Saint-Etienne

Moderators: Philippe KESTELYN, Gabor HOLLO, Jonathan JACKSON, Jost JONAS

- 348 From manual to computerized count: how to decide for a new cut off value for cell density to qualify corneas for graft?
HERRAG S, GAVET Y, THURET G, ACQUART S, CAMPOS-GUYOTAT L, GARRAUD O, GAIN P—Saint-Etienne
- 349 Establishing endothelial standards for the quality control of endothelial cell count in eye banks
ACQUART S, GAVET Y, THURET G, BRUN G, RACINE G, CAMPOS-GUYOTAT L, GARRAUD O, GAIN P—Saint-Etienne, Lausanne
- 350 Shouldn't we quantify the transparency and thickness of organ cultured corneas?
ACQUART S, GAVET Y, ZHAO M, MANISSOLLE C, THURET G, GARRAUD O, GAIN P—Saint-Etienne
- 351 New animal compound free medium for human corneal organ culture
MANISSOLLE C, GARRAUD O, ACQUART S, CAMPOS-GUYOTAT L, GUYOTAT D, GAIN P, THURET G—Saint-Etienne
- 352 Corneoscleral harvesting by automated trephine system: comparison- ophthalmologist with nurse
MANISSOLLE C, PEYRAGROSSE T, DEFREYN A, GARRAUD O, ACQUART S, THURET G, GAIN P—Saint-Etienne
- 353 Topical hydroalcoholic prodrug of cyclosporin A to prevent corneal graft rejection
rf BOURGES JL, VALAMANESH F, AGLA EK, LALLEMAND F, GURNY R, JEAN-MAURICE D, BESSEGHIR K, BEHAR-COHEN FF—Paris, Lausanne, Geneva
- 354 The role of T Helper 1 (Th1) and Th2 cytokines in corneal graft rejection
rf HOLAN V, VITOVA A, PINDJAKOVA J, KRULOVA M, ZAJICOVA A, FILIPEC M—Prague
- 355 Roles of Thrombospondin-1 and -2 in Maintaining Corneal Angiogenic Privilege
rf CURSIEFEN C, DANA MR, LAWLER J, STREILEIN JW—Erlangen, Boston
- 356 Effects of latanoprost 0.005% and the fixed combination dorzolamide/timolol on IOP and retrobulbar hemodynamics in glaucoma patients
rf MARTÍNEZ-GARCÍA AMG, SANCHEZ-SALORIO MSS, GARCÍA-FEIJOO JGF—Santiago de Compostela, Madrid
- 357 The rabbit's IOP after instillation of the amino acid L-arginin.HCl and antiglaucomatics mixture
rf OLAH Z, VESELOVSKY J, GRESSNEROVA S, VESELA A—Bratislava
- 358 Clinical experience with the Ahmed Valve implant in a non-tertiary ophthalmic unit
rf KALHORO A, MATAFTSI A, ATTENBOROUGH M, MEARZA A, BIDGOOD P, MCNIECE R, GILLESPIE I—Kingston-Upon-Thames
- 359 Evaluation of preoperative factors associated with success of mitomycin C needling revision for failed filtration blebs: a prospective study
rf GUTIERREZ CG, TEUS MT—Alcala de Henares
- 360 Comparison of anterior and posterior corneal curvatures (Orbscan II) in normal and glaucoma patients
rf HERNANDEZ VJL, TEUS MA, MARINA C, GIL R, SÁNCHEZ JM—Madrid
- 361 Central corneal thickness correlated with glaucoma damage and rate of progression
rf JONAS JB, STROUX A, VELTEN I, JUENEMANN A, MARTUS P, BUDDE WM—Heidelberg
- 362 Chronic ocular hypertension alters retrograde axoplasmic transport in adult rats
rf MAYOR - TORROGLOSA S, VILLEGAS-PÉREZ MP, SALAZAR JJ, RAMÍREZ JM, TRIVIÑO A, RAMÍREZ AI, COLL L, VIDAL-SANZ M—Murcia, Madrid
- 363 Chronic ocular hypertension induced degeneration of retinotectal afferents: long term neuroprotection with topical brimonidine
rf MAYOR - TORROGLOSA S, WOLDEMUSSE E, GARCÍA A, RUIZ G, BERNAL JM, WHEELER LA, VIDAL-SANZ M—Universidad de Murcia, Irvine, California
- 364 Retinal ganglion cell death after chronic elevation of intraocular pressure: a novel model of glaucoma in pigs
VECINO E, RUIZ J, GARCÍA M, HERNÁNDEZ M, URCOLA H, HERNÁNDEZ E, ARAIZ J, DURÁN JA—Vizcaya, Spain
- 365 Relation between polarimetric RNFLT and retinal sensitivity: frequency doubling technology and conventional perimetry show similar structure-function relationship
KOTHY P, KATSANOS A, HOLLÓ G—Budapest
- 366 Differences between glaucomatous patients with predominantly functional or structural deterioration
COOPS A, HENSON DB, KWARTZ AJ, FENERTY C, HARPER RA, SPENCER AF, MCLEOD D—Manchester
- 367 Sensitivity and specificity of analysis tools for detection of glaucoma with the Heidelberg Retina Tomograph II
FERRERAS A, MAYORAL C, POLO V, LARROSA JM, PUEYO V, PAJARIN AB, CASTILLO A, HONRUBIA FM—Zaragoza, Madrid
- 368 Optical Coherence Tomography (OCT): Retinal Nerve Fiber Layer thickness measurements to detect glaucomatous damage
FERRERAS A, POLO V, LARROSA JM, PUEYO V, MAYORAL C, PAJARIN AB, GARCIA-FEIJOO J, HONRUBIA FM—Zaragoza, Madrid
- 369 Diagnostic ability of scanning laser tomography assessed by means of Heidelberg Retina Tomograph II, to detect structural changes in the optic disc, in glaucoma suspects and glaucomatous eyes
MAYORAL C, LARROSA JM, POLO V, FERRERAS A, PUEYO V, LOPEZ MJ, HONRUBIA FM—Zaragoza
- 370 Diagnostic value of Optical Coherence Tomography (OCT) to detect structural damage in the Retinal Nerve Fiber Layer (RNFL) in glaucoma suspects and glaucomatous eyes
PUEYO V, LARROSA JM, POLO V, FERRERAS A, MAYORAL C, PAJARIN AB, HONRUBIA FM—Zaragoza
- 371 Correlation between standard automated perimetry global indices and Heidelberg retina tomograph parameters
PUEYO V, FERRERAS A, LARROSA JM, POLO V, MAYORAL C, PAJARIN AB, HONRUBIA FM—Zaragoza
- 372 Reproducibility of optic nerve head assessment and retinal nerve fiber layer thickness measurements using optical coherence tomography
LARROSA JM, FERRERAS A, PUEYO V, POLO V, MAYORAL C, LOPEZ MJ, HONRUBIA FM—Zaragoza
- 373 Heidelberg Retina Tomograph II: Multivariate analysis of structural parameters of the optic disc topography
LARROSA JM, POLO V, FERRERAS A, PUEYO V, MAYORAL C, MARTÍNEZ DE LA CASA JM, HONRUBIA FM—Zaragoza, Madrid
- 374 Optimum criteria for Optical Coherence Tomography (OCT) to detect Retinal Nerve Fiber Layer (RNFL) defects in glaucomatous eyes
POLO V, LARROSA JM, FERRERAS A, MAYORAL C, PUEYO V, MARTÍNEZ A, HONRUBIA FM—Zaragoza
- 375 Optic Nerve Head Parameters in Normal, Ocular Hypertensive and Glaucomatous eyes measured by Confocal Scanning Laser Tomography (Heidelberg Retina Tomograph II)
POLO V, FERRERAS A, LARROSA JM, MAYORAL C, PUEYO V, ANTÓN A, HONRUBIA FM—Zaragoza, Valladolid
- 376 Correlation between Standard Automated Perimetry Global Indices and Retinal Nerve Fiber Layer thickness measurements by means of Optical Coherence Tomography (OCT)
MAYORAL C, POLO V, FERRERAS A, LARROSA JM, PUEYO V, MARTÍNEZ A, HONRUBIA FM—Zaragoza
- 377 Clinical pathways in glaucoma elaborated by a new pupillographic test (patent pending)
rf KANDEL GL, KABACK M, SANCHEZ R—New York
- 378 Hypotensive and neuroprotective effect of antiglaucomatous drugs in an experimental glaucoma model
URCOLA JH, RUIZ J, GARCIA M, HERNÁNDEZ M, ARAIZ J, DURÁN J, VECINO E—Vizcaya, Spain
- 379 Scleral Patch Graft covered with Multilayer Amniotic Membrane Transplantation for the Management of the Conjunctival Erosion in the Implant Seton
FROMOW - GUERRA M, AYALA-FLORES M, ESPINOZA-NAVARRO J, ROMERO-CASTILLO L, GARCIDUENAS-MEJIA M—Mexico
- 380 Under a Sealed Scleral Flap, Effect of Trabeculectomy and/or Sclerectomy on Outflow Facility in Perfused Pig Eyes
XU W, NI Y, SCHAARAWY T, HAEFLIGER IO—Basel, Switzerland
- 381 G-probe use in cases with serious general state of patients (case report)
BUNIATYAN IY—Yerevan
- 382 Usage of G-probe diode laser in treatment of neovascular glaucoma after vein thrombosis in caucasian patients
BUNIATYAN IY—Yerevan
- 383 Selective laser trabeculoplasty vs argon laser trabeculoplasty in open angle glaucoma
CELLINI, BERNABINI B, LEONETTI P, CAMPOS EC—Bologna
- 384 Simultaneous bilateral trabeculectomy
GUTIERREZ CG, TEUS MT—Alcala de Henares
- 385 Therapeutic Applications of Contact Lenses in Myopia Control
rf MAHOMED A, PUNYAMOONWONGSA P, TIGHE B—CEAC
- 386 Comparison of early and middle-term microscopic morphological corneal response after PRK, LASEK and alcohol-free LASEK
rf NUBILE M, LANZINI M, COSTANTINO O, MASTROPASQUA L—Chieti, Italy

Keynote Lectures

BRON, A: Friday, 18:00
 CUNHA-VAZ, J: Monday, 15:45
 DELAMERE, N: Sunday, 15:45
 DRECOLL, EL: Friday, 17:15
 PFLUGFELDER, S: Saturday, 10:15
 WEST, S: Saturday, 15:45
 ZRENNER, E: Sunday, 10:15

ABAD M: 156, 1261, 1265
 ABECIA E: 146
 ABU EL ASRAR A: 105, 1213, 1216, 1157
 ACOSTA AC: 3461
 ACQUART S: 349, 350
 AGOSTINI HT: 3233
 AGUSTIN GONZALO AGUSTIN M: 263
 AHAD M: 179
 AHMAD I: 2434
 AKHTAR S: 320, 1442
 ALJAMAL RT: 234d
 ALL-ERICSSON C: 214
 ALLEN RJ: 313
 ALYAHYA GA: 234c
 ANASTASSIOU G: 2144
 ANDERSON OA: 115, 256, 2428
 ANTON LOPEZ AAL: 234, 1128
 ARDEN GB: 3251
 AREND O: 2412
 ARMOUR R H: 153
 ARSENIJEVIC Y: 2435
 AUGOOD C: 3221
 AUGUSTIN HG: 3235
 AVELEIRA C: 124
 AYALA M: 183, 1235
 AYDIN P: 3241, 3341
 ÅSTRÖM EM: 160, 1446
 BALAYRE SB: 1262, 1263
 BANFI S: 2353
 BAPTISTA AMG: 152
 BAPTISTA P: 2466
 BARBUR JL: 3144, 3254
 BARRAQUER J: 1362, 1365
 BARRAQUER R: 3464
 BASSIME L: 231
 BEHNDIG A: 340, 2252, 3436
 BENSON S E: 2462
 BERENDSCHOT TTJM: 119, 120
 BERGUA A: 225
 BERNARDES R: 2362, 2463
 BETIS F: 1452
 BEUERMAN R: 1241
 BIANCIOTTO C: 2341, 234b
 BITSIOS P: 3143
 BLAISE P: 1422
 BODAGHI B: 1214
 BOGDANICI C: 2346
 BOUFFIQUX C: 1421
 BOURGES JL: 353, 3337
 BRINKMANN R: 3446
 BRON A: 1341, 2112
 BRUENECH JR: 1343
 BUNIATYAN IY: 381, 382
 BYSTRÖM B: 1444
 CACHO I: 270
 CARNOVALE-SCALZO G: 223

CARVALHO M: 112
 CASANOVA C: 2422
 CASTILHO A: 236, 2326
 CATARINO S: 1333
 CELLINI: 383
 CHAKRAVARTHY U: 3224
 CHAUHAN BC: 3164
 CHIDLOW G: 238, 2328
 CHOH V: 3266
 CHUNG A: 128
 CHYLACK LT: 2451
 CIMINO L: 2121
 CLAERHOUT I: 3333
 COLLINS C E: 1133
 COOPS A: 366
 CORCOSTEGUI B: 2166
 COSCAS G: 1254, 1354
 CUNHA-VAZ J: 2365
 CURSIEFEN C: 355, 2116, 3231, 3332, 3339
 DALKE C: 2153, 3351
 DAMATO B: 1222, 2244
 DANA R: 2333
 DE ALMEIDA VMN: 2426
 DE BAERE E: 1325
 DEB N: 149, 323
 DE BOER JF: 3444
 DE GREEF S: 1423
 DE HOZ R: 172
 DE KEYZER K: 1323
 DELAMERE N.A.: 1331
 DEL MORAL MARTÍNEZ MI: 264
 DENIS P: 2414
 DESJARDINS L: 1224, 2242
 DE SMET M: 1311, 1312, 2164, 3126
 DE SOUZA RAMALHO P: 134, 1152
 DEUTMAN A F: 2162
 DEWIT D: 191, 311
 DIAS J: 1353
 DICK A: 1313, 2334
 DIEUDONNE SC: 131
 DILLEN K: 1425
 DOAN S: 1416
 DOELEMAYER A: 3413
 DOHLMAN C: 1462
 DONG X: 1232
 DREXLER W: 3443
 DUA HS: 2211, 2433
 DUARTE L: 130
 DUBBELMAN M: 3263
 DWARIKA D: 328
 EASTY D: 2113
 EL-AMIR AN: 1455
 ELGOHARY MA: 188, 1435
 EL SHEHA H: 222, 2124
 ENZ R: 2133
 ERDELYI B: 2313
 ESPINOZA-NAVARRO J: 101
 FAGERHOLM P: 1161, 1162
 FALSINI B: 3322
 FARIA P: 2224
 FARKAS Á: 147
 FELTGEN NF: 2266
 FERNANDES A: 2323
 FERNANDES R: 314, 3355

FERNANDEZ DURANGO R: 3163
 FERNANDEZ V: 1461
 FERNANDO A: 125, 189
 FERRERAS A: 367, 368
 FERRER RODRIGUEZ C: 211, 2321
 FIELDER AR: 103, 1156
 FITZKE F: 2361
 FLETCHER AE: 3223
 FORRESTER J: 2332
 FRANCO S: 337
 FRANKLIN V: 169, 330
 FRIS M: 1336
 FROMOW - GUERRA M: 379
 FRUSCHELLI M: 181
 FUCHSJÄGER-MAYRL G: 1123
 GAIN P: 344, 345
 GALAND A: 1436
 GANDOLFI S: 2413, 3315
 GAN L: 3336
 GARHOFER G: 1125
 GAUBA V: 267, 326
 GAVET Y: 133, 346
 GAVIOLI IG: 247
 GEERARDS AJM: 3133
 GEHL Z: 246
 GEORGAKOPOULOS C: 322
 GICQUEL JG: 1163, 1445
 GIL R: 3433, 3434
 GIRAO H: 198
 GIRAUD JMG: 150
 GLASSER A: 3262, 3365
 GLAVINI A: 1443
 GOMBOSS K: 185
 GOMES J: 2212
 GOMEZ-RAMIREZ AM: 138
 GONG N: 341
 GONZALEZ-MEIJOME JM: 333
 GONZALVEZ BG: 118
 GRASSI F: 196
 GRAW J: 1136, 2155
 GRIFFITH M: 1468
 GRUNWALD JE: 3323
 GUEX-CROSIER Y: 1414
 GUTHOFF R: 3261
 GUTIERREZ CG: 359, 384, 3159
 GWIAZDA J: 1245
 HABIB MS: 1434
 HADJISTILIANOU T: 212, 2141
 HAGEMAN G: 2161
 HAMEDANI M: 1412
 HANSEN LH: 2264
 HAOUCHINE B: 3123
 HARDING JJ: 2251
 HART A: 2151
 HATTAR S: 3141
 HATTENBACH LO: 2262
 HAUFSCCHILD T: 3212
 HEEGAARD S: 204, 2149
 HEGDE KR: 2452
 HEIJL A: 2411
 HELLSTROM A: 3342
 HENRICH PB: 1453
 HERA R: 129
 HERBA E: 260, 2123

HERBORT CP: 1215, 1315
 HERNANDEZ VJL: 338, 360, 3417
 HERRAG S: 347, 348
 HICKS CR: 1465
 HOLAN V: 354, 3338
 HOLLÓ G: 3213
 HOLMES J. M.: 228
 HYVARINEN L: 3345
 IOMDINA EN: 250, 3115
 ISLAM N: 187
 ISPOLOVA EA: 3117
 JACKSON AJ: 3132
 JACOBSON L: 3343
 JAEGLE H: 3253
 JAHN CE: 193, 1433
 JASTANEIAH SJ: 3335, 3432
 JOHN N: 3353
 JONAS J: 141, 361, 3244, 3418
 JORGE J: 269, 306
 JOUSSEN J: 3232
 KAARNIRANTA K: 1145
 KADOR P: 2455
 KAIMBO WA KAIMBO D: 316
 KAKAR M: 195
 KALHORO A: 229, 358, 3158
 KAMPETER B: 1432, 3416
 KANDEL GL: 377, 2227
 KARACORLU M: 1252, 2265
 KARLSSON J-O: 1332
 KASSNER C: 244
 KAWA P: 216, 2126
 KAWASAKI A: 3142
 KEIJSER S: 2145
 KHAN AJ: 145
 KING G: 3162
 KINNUNEN K: 301
 KIRCHER K: 230
 KIVELA T: 1221
 KJELGREN D: 1142
 KLEIN A: 1321
 KNEZY K: 259
 KNOBLAUCH K: 3255
 KNOP E: 1441, 2331
 KOCH P: 1424
 KOJIMA M: 159, 1268
 KOLKO M: 116
 KOLODIJASCHNA J: 235, 1129
 KOOPMANS SA: 3462
 KOPPEN C: 3134
 KOSHITZ IN: 3118
 KOTHARY PC: 241
 KOTHY P: 365
 KOTLIAR K: 232, 1126, 3111
 KOULIKOVSKA M: 331
 KOZAK LR: 2421
 KREISSIG I: 1251
 KUJALA E: 2241
 LABALETTE PL: 180
 LACHAPPELLE P: 2423
 LANGENBUCHER A: 335
 LANZL I: 249, 1124, 3116
 LARROSA JM: 372, 373
 LAUDE A: 114
 LAWRENSON JG: 1344

- LÜJTJEN DRECOLL E: 2134
 LEE E: 1367
 LEE HK: 158, 1267
 LEONARDIA A: 2114
 LEON CR: 1464
 LESCH B: 257
 LEYS A: 2163
 LIBONDI T: 312
 LINDEGAARD J: 2143
 LINDEN C: 308
 LINHARES JMM: 266
 LIRA M: 162, 163
 LIU C: 1361
 LLOYD AW: 1469
 LUKSCH A: 102, 1155
 MACEDO AF: 220, 2226
 MADILL SA: 218, 2128
 MAHOMED A: 167, 385, 3437
 MAJO F: 2432
 MANGANELLI C: 2314
 MANISSOLLE C: 351, 352
 MANN AM: 165, 168
 MANSOURI K: 3155
 MARQUES C: 197
 MARTÍNEZ-GARCÍA AMG: 356, 3156
 MARTIN L: 3344
 MARTINS ALMEIDA MELO P: 253
 MARUYAMA K: 3331
 MAVRIKAKIS I: 1364
 MAY CA: 2131, 2231
 MAYOR-TORROGLOSA S: 362, 363, 3419, 341a
 MAYORAL C: 369, 376
 MÜLLER LJ: 3435
 MCDERMOTT AM: 2311
 MEHTA JS: 1466
 MEIGEN T: 2424
 MENDEZ MC: 2347, 2348
 MENKE MN: 3412
 MEYER-SCHWICKERATH RMS: 3243
 MICHAEL R: 1431
 MIDELFART A: 1233
 MILANO G: 3411
 MISIUK-HOJLO M: 137
 MISSOTTEN GS: 206, 2245, 2248
 MISSOTTEN T: 1114, 1115
 MOCHIZUKI M: 1211
 MODY V: 194
 MOISEEVA IM: 3112
 MOORE JE: 1467
 MORA P: 242, 1415
 MORILLA A: 208, 215
 MOSCHOS MM: 1411
 MOURIAUX F: 205, 2247
 MUENSTER D: 2355
 MUGHAL S: 113, 139
 MUNOZ MORALES AM: 123, 2125
 MUQIT MMK: 106
 NAGARAJ RH: 1337, 2456
 NAGY ZZ: 336
 NASCIMENTO JCN: 1352
 NASCIMENTO SMC: 2425
 NIEDERER P: 3445
 NIELSEN KN: 321
 NILSSON M: 268
 NIRANKARI VS: 2213
 NI Y: 251
 NOURI M: 1463
 NOWILATY SR: 126, 329, 1356
 NUBILE M: 386, 1165, 3438
 NUNES S: 2465
 O'BRIEN T: 2115
 OBROSOVA IG: 2324
 OCKRIM ZK: 122, 2461
 OKANO T: 142
 OLAH Z: 357, 3157
 ONO S: 2335
 ORGUL S: 3214
 OSBORNE NN: 2132, 2233, 3311
 OWENS H: 2312
 PANTELEEVA OG: 210, 224
 PAQUES M: 2263
 PAREL JM: 3463
 PATIL R: 2234
 PAULA JS: 3352
 PAUL B: 1363
 PÅLSSON AZ: 199
 PEDROSA-DOMELLÖF F: 173, 1141
 PELLEGRINI G: 2431
 PENAS S: 136, 148
 PEREIRA FIGUEIRA J: 3122
 PEREIRA P: 1234, 2254
 PETERSEN A: 243
 PETROPOULOS I: 3326
 PFLUGFELDER S: 2214
 PHARMAKAKIS N: 182, 192
 PICCIRILLO V: 213
 PICHLER A: 171
 PIERRE-KAHN VPK: 107
 PINELLO L: 325
 PINILLA I: 132, 302
 PINNA A: 315, 3356
 PINTO PD: 262
 PIPERNO-NEUMANN S: 2246
 PLAZAS A: 104, 1357
 PLEYER U: 1314, 3334
 PODOLEANU A: 3442
 POJDA-WILCZEK D: 108, 2122
 POLO V: 374, 375
 POLSKA E: 1122
 POPPER M: 1164
 POURNARAS CJ: 2261, 2267, 3325
 PRUENTE Ch: 3215
 PRZYDRYGA J: 170
 PUEYO V: 370, 371
 PUUSAARI I: 2342
 QUADRADO MJ: 154, 1166
 QUEIROS A: 227, 271
 RAMIREZ AI: 144
 RAVI N: 3362
 REITSAMER H: 2152, 3245
 RESSINIOTIS T: 310, 1135
 RICHARD G: 2167
 RIVA CE: 2232, 3321
 ROBBIE S J: 176
 ROCHA DE SOUSA A: 2223, 2325
 RODRIGUES LG: 252
 ROJAS B: 1143
 ROLDAN-PALLARES M: 1454
 ROMANOWSKA DIXON B: 2343, 2345
 ROSEN R: 3125
 ROZEMA J: 1324
 RUIZ-LAPUENTE C: 1351, 3153
 RUIZ MORENO JM: 1255
 SAHEL J: 2364, 3312
 SALAMA BS: 174, 255, 2427
 SALAZAR JJ: 143
 SALEH G: 274
 SALOMON E: 309
 SANDER B: 3441
 SANDHU R: 109, 111
 SANDINHA MT: 2243
 SAORNIL MA: 2349, 234a
 SARFARAZI FM: 3364
 SAUVÉ Y: 303, 304
 SAW SM: 1243
 SCHLINGEMANN RO: 1151, 3234
 SCHMETTERER L: 3161, 3211, 3324
 SCORCIA V: 334
 SELAND J: 3227
 SEONG GJ: 245
 SEREGARD S: 1225
 SERES A: 1355
 SERGIENKO N: 3363
 SETHU MADHAVAN A: 307
 SHANG F: 2253
 SHIEW M: 184, 248
 SIDEROUDI TI: 240
 SIEGEL LI: 233, 1127
 SILVA M: 273
 SIVAGNANAVEL V: 121, 1154
 SJÖSTRAND J: 110
 SJÖ LD: 2142
 SJO NC: 201, 2146
 SKINNER KC: 155, 1167
 SMITH AF: 327, 3421
 SOBRADO-CALVO P: 127
 SODERBERG PG: 2453
 SOLTANINIA J: 157, 1266
 SOUBRANE G: 2165, 3225
 SPILEERS W: 3252
 STALMANS I: 1322
 STANESCU D: 175
 STODTMEISTER R: 3242
 STRUCK HG: 1334
 SUMMANEN P: 1153
 SUNDARAM V: 161, 319, 1447, 2317
 SVETLOVA OV: 3114
 SZABO V: 1131
 SZLITER EA: 332
 TAHHAN M: 186, 203, 2148
 TAN D: 1246
 TANDON R: 1366
 TASSIGNON MJ: 3361
 TEIXEIRA C: 190, 1132
 TESSEM MB: 324
 TEUS MA: 1253
 THURET G: 343, 1264
 TIFFANY J: 164
 TIGHE B: 166, 318, 2316
 TONINI M: 202, 2147
 TOPOUSIS F: 3226
 TREVITHICK JR: 2454
 TUISKU ISJ: 2315
 UNGARO N: 3414
 URBAN E: 178
 URCOLA JH: 378
 UUSITALO H: 3151
 VA'MOS R: 305
 VAIDEANU D: 1134, 3152
 VAN DER HEIJDE RGL: 3264
 VAN DER WERF F: 1345
 VAN GINDERDEUREN R: 207, 2344
 VAN HEYNINGEN V: 2351
 VAN NORREN D: 117
 VAN VELTHOVEN MEJ: 3124
 VARANDAS J: 2464
 VARGAS-MARTÍN F: 272, 3354
 VARSANYI B: 2467
 VAUDAUX J: 1413
 VECINO E: 364
 VELARDE JI: 3431
 VERBRAAK FD: 3121
 VERONESE RODRIGUES ML: 1111
 VIDAL-SANZ M: 3313
 VIDAL LÓPEZ J: 226, 261
 VIEIRA DE SOUZA N: 151
 VIGANDER K: 217, 2127
 VILA J: 265
 VINH VV: 221
 VIRTAMO T: 317, 3357
 VISSER ES: 3131
 VITOVA A: 342
 VOIGT M: 135
 VOROS GM: 177, 209
 VOSSMERBAEUMER U: 339, 1144
 VRENSSEN GFJM: 1342
 WADDELL JM: 2322
 WATSON S: 1368
 WEALE R: 3265
 WEGENER A: 1231, 2154
 WEIGERT G: 3327
 WEIR RE: 2221
 WERNER J: 3256
 WEST-MAYS J: 2354
 WHEELER LA: 3314
 WIEDERHOLT M: 3415
 WILLERMAIN F: 1113
 WILSON C: 2111
 WILSON WS: 239, 2329
 WITTBRODT J: 2352
 WONG TY: 1244
 WOOD JPM: 237, 2327
 WRIDE NK: 3154
 XU W: 380
 YAMAKI K: 1112, 1212
 YAP E: 1242
 YILMAZ G: 140, 1256, 1451
 YINON U: 258
 YORIO T: 3165
 YOUNG IS: 3222
 ZAIDI FH: 219, 2222, 2225
 ZARNOWSKI T: 1335
 ZASEEVA MV: 3113
 ZAWINKA C: 1121
 ZOGRAFOS L: 1223
 ZRENNER E: 2363

EVER gratefully acknowledges the sponsoring by the following companies:

Main sponsor



Major sponsors







Sponsors



About the programme book

This programme book is organised chronologically. The sessions are colour-coded:



FP = Free Paper session

SIS = Special Interest Symposium

rf = Rapid Fire presentation

FRO = Funds for Research in Ophthalmology

Three digit numbers refer to posters, four digit numbers refer to oral presentations.

See more richly

Allowing patients to see the world with their own eyes – that's what we work on every day. And we know that it's what you work on every day too. All over the world, patient by patient, eye care professionals are maintaining and improving people's eyesight. At Carl Zeiss we continue to focus on the science of vision so that we can provide the intelligent tools that you need to help your patients see the world more richly than ever before.

It's what happens when we all put ...

Vision in Focus



© 2004 Carl Zeiss Meditec, Inc.



Carl Zeiss Meditec AG
07745 Jena
Germany
Tel.: +49 (0) 36 41 / 2 20-3 33
info@meditec.zeiss.com
www.meditec.zeiss.com

Carl Zeiss Meditec Inc.
Dublin, CA 94568
USA
Phone: +1 925 557 4100
info@meditec.zeiss.com
www.meditec.zeiss.com



	Gemini I	Gemini III	Pegasus	Vega	Fenix I	Fenix III	PC Room
Friday 24 September 2004							
14:00 - 17:00	How to organize clinical studies — A SMITH	Visual fields in optic nerve and pathway diseases — P AYDIN		Electrophysiology — G HOLDER			
17:00 - 17:15	EVER Opening Ceremony						
17:15 - 18:00	Ophthalmic Research lecture: TGFβ in the anterior eye segment: its significance for immunoprivilege and glaucoma — E LUTJEN DRECOLL						
18:00 - 18:45	EVER Lecture: Of Puzzles and Paradoxes — A BRON						
18:45 - 19:30	EVER Extraordinary General Assembly						
19:30 - 22:00	EVER Welcome Garden Party						

EVER 2004 — Vilamoura, Portugal, September 24–27

	Saturday 25 September 2004		Sunday 26 September 2004		Monday 27 September 2004	
08:30 - 10:00	FP: Uveitis AD DICK, F BEHAR-COHEN	FP: Physiology - Pharmacology JO HAEFLIGER, L SCHMETTERER	FP: Genetics A CHURCHILL, J GRAW	FP: Anatomy - Cell Biology E KNOP, F VAN DER WERF	FP: Retina 1 - Physiology / Physiopathology G COSCAS, P SUUMANEN	FP: Cornea 1 Clinical P FAGERHOLM
10:15 - 11:00	Keynote lecture: Mechanisms of corneal epithelial diseases in dry eye SC PFLUGFELDER					
11:00 - 12:30	Vogt-Koyanagi-Harada disease A ABU EL ASRAR, CP HERBORT	Improving classification of malignant uveal melanoma — T KIVELA, E MIDENA	FP: Lens UVR R MICHAEL	Epidemiology and genetics of refractive error SM SAW, E YAP, D T TAN	FP: Retina 2 - Pharmacology J KREISSIG, M KARACORLU	FP: Cornea 2 Clinical HS DJIA, N EHLERS
14:00 - 15:30	New therapeutic modalities in uveitis MD DE SMET, U PLEYER	FRO 1 MJ TASSIGNON	FP: Lens Biochemistry T LIBONDI	Gordon RUSKELL memorial symposium F VAN DER WERF	FP: Retina 3 - Subretinal neovessels - Laser treatment — A LEYS, G SOUBRANE	Keratoprosthesis 1 C LIU
15:45 - 16:30	Keynote lecture: Cataract at the Cross Roads: Increasing blindness, challenges for research — S WEST					
16:30 - 17:30	POSTER Session: Retina - Cornea 1 - Anatomy / Cell Biology - Uveitis - Lens					
17:30 - 19:00	Scleritis Y GUEX-CROSIER	FRO 2 MJ TASSIGNON	FP: Lens Clinical A WEGENER, P SODERBERG	FP: Cornea Molecular Biology B BYSTRÖM, PL DIGHIERO	FP: Retina 4 - Surgery C POURNARAS, P WIEDEMANN	Keratoprosthesis 2 C LIU
19:00 - 20:00	Business meetings of the scientific sections					

08:30 - 10:00	Highlights of therapy for external eye disease A BRON, C WILSON	FP: Neuro-ophthalmology 1 P AYDIN, A HELLSTROM	Morphology of the inner retina and optic nerve related to glaucoma — CA MAY	OOF 1 L DESJARDINS, E MIDENA	Workshop: Mouse Model & Phenotyping J GRAW	EURETINA: New therapeutic options in AMD G RICHARD
10:15 - 11:00	AER lecture: From gene to therapy: the long way to understand and cure retinal diseases — E ZRENNER					
11:00 - 12:30	Dry Eye HS DJIA, J GOMEZ	FP: Neuro-ophthalmology 2 J BARBUR	Physiology and pharmacology of the optic nerve — N DELAMERE	OOF 2 T KIVELA	Oxidation and cataract A BEHNIG	Retinal vein occlusions M KARACORLU, C POURNARAS
14:00 - 15:30	FP: Cornea 3 Tears - Dry Eye S PFLUGFELDER, P MAUDGAL	FP: Physiology - Pharmacology - Animal Studies — N OSBORNE, C WILSON	Dendritic cells-key regulators of ocular antigen presentation — E KNOP, U PLEYER	OOF 3 R VAN GINDERDEUREN, S SEREGARD	Lens development and genetics J GRAW	The European Vision Institute. Phenotyping of AMD — J CUNHA-VAZ. <i>Eur. Vision Institute</i>
15:45 - 16:30	Keynote Lecture: Astrocyte form and function: implications for glaucoma — N DELAMERE					
16:30 - 17:30	POSTER session: Pathology - Oncology - Neuro-ophthalmology - Physiology - Pharmacology - Vision Sciences					
17:30 - 19:00	New combinations in glaucoma therapy A HEIL	FP: Vision Sciences W SPIELERS	Stem and progenitor cells of the eye Y ARSENEVIC, E KNOP, F MUNIER	OOF 4 E MIDENA	Potentials for nutritional & therap. prevention of cataract — SD VARMA, P SODERBERG	FP: Retina 5 - Instrumentation & Techniques S BENSON
20:00 - 23:00	EVER Congress Dinner					

08:30 - 10:00	Ocular biomechanics K KOTLAR	New developments in OCT MD DE SMET	Contact lenses: Applications & Complications M RUBINSTEIN, HIM VOLKER-DIEBEN	Pupil function: new concepts and clinical implications — A SARRAI, J BARBUR	FP: Glaucoma 1 JB JONAS, M WIEDERHOLT	Ocular endothelins: A role in ocular disease? T YORO
10:15 - 11:00	EVER General Assembly					
11:00 - 12:30	Endothelin-1 in glaucoma and other ocular diseases — T HAUFSCHELD, S ORGUL	EUREYE A FLETCHER	Molecular mechanisms of angiogenesis and lymphangiogenesis — HT AGOSTINI	Ophthalmodynamometry: The past and the future — P AYDIN	Advances in colour vision assessment and its clinical applications — J BARBUR	Accommodation in the intact eye GFIM VREISEN, EA WEALE
14:00 - 15:30	Neuroprotection in the visual system M VIDAL-SANZ, N OSBORNE	Ocular blood flow in AMD C RIVA, L SCHMETTERER	FP: Corneal Grafting R DAMA, U PLEYER	Visual function in pediatric neuro-ophthalmology — P AYDIN	FP: Genetics & Epidemiology J GRAW, A FLETCHER	Accommodative IOL part 1 R BARRAQUER, R MICHAEL
15:45 - 16:30	Keynote lecture: Characterization of Diabetic Retinopathy Phenotypes, Perspectives for improved management — J CUNHA-VAZ					
16:30 - 17:30	POSTER session: Molecular Biology - Epidemiology - Cornea 2 - Cornea 3 - Glaucoma - Refractive Surgery					
17:30 - 19:00	FP: Glaucoma 2 L SCHMETTERER	Health economics A SMITH	FP: Refractive Surgery P KESTELYN	Novel ophthalmic technologies II T MISSOTTEN	International ophthalmology in developing countries — A BIALASEWICZ	Accommodative IOL part 2 R MICHAEL, R BARRAQUER